<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006083</article-id><article-id pub-id-type="pmc">PMC11859321</article-id><article-id pub-id-type="doi">10.3390/ph18020271</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00271</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Brain Glucose Hypometabolism and Brain Iron Accumulation as Therapeutic Targets for Alzheimer&#x02019;s Disease and Other CNS Disorders</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9505-9264</contrib-id><name><surname>Rao</surname><given-names>Indira Y.</given-names></name><xref rid="af1-pharmaceuticals-18-00271" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Hanson</surname><given-names>Leah R.</given-names></name><xref rid="af1-pharmaceuticals-18-00271" ref-type="aff">1</xref><xref rid="af2-pharmaceuticals-18-00271" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6373-0794</contrib-id><name><surname>Frey</surname><given-names>William H.</given-names><suffix>II</suffix></name><xref rid="af1-pharmaceuticals-18-00271" ref-type="aff">1</xref><xref rid="af2-pharmaceuticals-18-00271" ref-type="aff">2</xref><xref rid="c1-pharmaceuticals-18-00271" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Couture</surname><given-names>R&#x000e9;jean</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Scarselli</surname><given-names>Marco</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00271"><label>1</label>HealthPartners Center for Memory and Aging, Saint Paul, MN 55130, USA; <email>rao00111@umn.edu</email> (I.Y.R.); <email>leah.r.hanson@healthpartners.com</email> (L.R.H.)</aff><aff id="af2-pharmaceuticals-18-00271"><label>2</label>HealthPartners Institute, Bloomington, MN 55425, USA</aff><author-notes><corresp id="c1-pharmaceuticals-18-00271"><label>*</label>Correspondence: <email>alzheimr@umn.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>271</elocation-id><history><date date-type="received"><day>10</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>31</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Two common mechanisms contributing to multiple neurological disorders, including Alzheimer&#x02019;s disease, are brain glucose hypometabolism (BGHM) and brain iron accumulation (BIA). Currently, BGHM and BIA are both widely acknowledged as biomarkers that aid in diagnosing CNS disorders, distinguishing between disorders with similar symptoms, and tracking disease progression. Therapeutics targeting BGHM and BIA in Alzheimer&#x02019;s disease can be beneficial in treating neurocognitive symptoms. This review addresses the evidence for the therapeutic potential of targeting BGHM and BIA in multiple CNS disorders. Intranasal insulin, which is anti-inflammatory and increases brain cell energy, and intranasal deferoxamine, which reduces oxidative damage and inflammation, represent promising treatments targeting these mechanisms. Both BGHM and BIA are promising therapeutic targets for AD and other CNS disorders.</p></abstract><kwd-group><kwd>brain glucose hypometabolism</kwd><kwd>brain iron accumulation</kwd><kwd>Alzheimer&#x02019;s disease</kwd><kwd>intranasal insulin</kwd><kwd>intranasal deferoxamine</kwd><kwd>intranasal treatment</kwd><kwd>neuroinflammation</kwd><kwd>brain cell energy</kwd><kwd>nose-to-brain delivery</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00271"><title>1. Introduction</title><p>Alzheimer&#x02019;s disease (AD) is a neurodegenerative disorder characterized by progressive memory loss, impaired cognition, confusion, disorientation, and other symptoms associated with dementia. It is the most common neurodegenerative disorder and can severely impair the quality of patients&#x02019; lives. A 2024 report from the Alzheimer&#x02019;s Association reported that 6.9 million Americans age 65 and older have AD, showing how prevalent the disorder is in older adults [<xref rid="B1-pharmaceuticals-18-00271" ref-type="bibr">1</xref>]. Caregivers of those with AD provided an estimated 18.4 billion hours of unpaid assistance in 2023, demonstrating the large financial burden and time-intensive nature of caregiving [<xref rid="B1-pharmaceuticals-18-00271" ref-type="bibr">1</xref>]. More recent research efforts have been focused on developing disease-modifying therapies that are specific to treating AD [<xref rid="B2-pharmaceuticals-18-00271" ref-type="bibr">2</xref>]. However, many treatments that have the potential to ameliorate symptoms of AD and other CNS disorders involving reduced brain cell energy and increased neuroinflammation have not received sufficient attention.</p><p>One of the primary reasons why there are few, if any, highly effective treatments being prescribed for patients with AD, is that the etiology of the disease is not completely understood. For many decades, the amyloid hypothesis has prevailed, which originally proposed that extracellular aggregates of amyloid beta initiate cellular pathways that ultimately lead to cell death [<xref rid="B3-pharmaceuticals-18-00271" ref-type="bibr">3</xref>]. However, several clinical trials of drugs that reduced amyloid beta plaques were not effective in treating AD. There are, however, two recent immunotherapy treatments, donanemab and lecanemab, that have been approved for AD although their safety and effectiveness are not entirely clear [<xref rid="B4-pharmaceuticals-18-00271" ref-type="bibr">4</xref>]. Currently, another prevalent hypothesis for what causes AD is the abnormal accumulation of hyperphosphorylated tau (p-tau). The neurofibrillary tangles that form with accumulation of p-tau have shown a stronger correlation with memory loss and disease progression than amyloid beta plaques and disease-modifying therapies for this hypothesis are being developed [<xref rid="B5-pharmaceuticals-18-00271" ref-type="bibr">5</xref>].</p><p>Although it is important to better understand what causes AD, there are also reasons to consider therapeutics that target common mechanisms across neurological disorders. Two common mechanisms contributing to multiple neurological disorders are brain glucose hypometabolism (BGHM) and brain iron accumulation (BIA) as described below (<xref rid="pharmaceuticals-18-00271-f001" ref-type="fig">Figure 1</xref>). Currently, BGHM and BIA are both widely acknowledged as biomarkers that aid in diagnosing CNS disorders, distinguishing between those with similar symptoms, and tracking disease progression [<xref rid="B6-pharmaceuticals-18-00271" ref-type="bibr">6</xref>]. This narrative review expands on our previous paper [<xref rid="B6-pharmaceuticals-18-00271" ref-type="bibr">6</xref>] which reviewed the brain regions exhibiting BGHM and/or BIA in AD and Parkinson&#x02019;s Disease (PD). We address the evidence for the therapeutic potential of targeting BGHM and BIA, the many neurodegenerative disease mechanisms in which these biomarkers are involved, and treatments that target each.</p><sec id="sec1dot1-pharmaceuticals-18-00271"><title>1.1. Reduced Insulin Signaling and Brain Glucose Hypometabolism in AD and Other CNS Disorders</title><p>Although the brain makes up a very small percentage of the total body weight, it utilizes about 20% of the total oxygen and calories to meet its metabolic needs [<xref rid="B7-pharmaceuticals-18-00271" ref-type="bibr">7</xref>]. With glucose being the main source of energy in the brain, the constant uptake and metabolism of glucose is necessary to ensure normal functioning of the cells. The absorption of glucose into cells is dependent on the uptake and binding of insulin to receptors on the cell surface. Insulin signaling is responsible for effective glucose uptake and metabolism, without which the cell would have insufficient energy to function normally. Type 2 Diabetes Mellitus, hyperinsulinemia, and both systemic and brain insulin resistance, all of which show dysregulation of insulin signaling, increase the susceptibility to developing AD [<xref rid="B8-pharmaceuticals-18-00271" ref-type="bibr">8</xref>].</p><p>Brain glucose hypometabolism has been observed in a variety of CNS diseases (<xref rid="pharmaceuticals-18-00271-t001" ref-type="table">Table 1</xref>). It has been hypothesized that the lack of glucose uptake and metabolism in the brain would lead to a loss of cellular energy resulting in the inability of the brain to carry out its normal functions and to maintain homeostasis which could ultimately lead to cell degeneration [<xref rid="B6-pharmaceuticals-18-00271" ref-type="bibr">6</xref>].</p></sec><sec id="sec1dot2-pharmaceuticals-18-00271"><title>1.2. Brain Iron Accumulation in AD and Other CNS Disorders</title><p>Iron is essential for brain function as it is necessary for processes such as oxygen transport, neurotransmission, and myelin homeostasis, amongst others [<xref rid="B9-pharmaceuticals-18-00271" ref-type="bibr">9</xref>]. Iron is mainly bound to iron-binding proteins in a cell. However, iron can also be found in its free state where it is not associated with proteins, and in this state, it is referred to as labile iron [<xref rid="B10-pharmaceuticals-18-00271" ref-type="bibr">10</xref>]. Labile iron catalyzes the Fenton reaction, which results in the formation of reactive oxygen species (ROS) that can cause oxidative stress and oxidative damage within the cell [<xref rid="B11-pharmaceuticals-18-00271" ref-type="bibr">11</xref>]. Excessive labile iron accumulates in specific regions of the brain in various brain diseases (<xref rid="pharmaceuticals-18-00271-t001" ref-type="table">Table 1</xref>) where it contributes to the neuroinflammation characteristic of many CNS disorders.</p><p>Ferroptosis is an iron-dependent cell death pathway observed in AD and other neurodegenerative diseases [<xref rid="B12-pharmaceuticals-18-00271" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceuticals-18-00271" ref-type="bibr">13</xref>]. Ferroptosis is morphologically, biochemically, and genetically distinct from apoptosis, necrosis, and autophagy and requires iron-dependent accumulation of lipid ROS and leads to cell death [<xref rid="B11-pharmaceuticals-18-00271" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceuticals-18-00271" ref-type="bibr">12</xref>]. Although ferroptosis continues to be explored in terms of its mechanism, chelating labile iron can help to prevent neuronal death via ferroptosis in AD.</p></sec></sec><sec id="sec2-pharmaceuticals-18-00271"><title>2. BGHM and BIA Occur in Many CNS Disorders</title><p>BGHM and BIA occur in a number of CNS disorders. <xref rid="pharmaceuticals-18-00271-t001" ref-type="table">Table 1</xref> presents a summary of many CNS disorders that show BGHM and BIA as demonstrated by fluorodeoxyglucose positron emission tomography (FDG-PET) and quantitative susceptibility mapping magnetic resonance imaging (QSM-MRI).</p><table-wrap position="anchor" id="pharmaceuticals-18-00271-t001"><object-id pub-id-type="pii">pharmaceuticals-18-00271-t001_Table 1</object-id><label>Table 1</label><caption><p>CNS disorders with BGHM and/or BIA as demonstrated by FDG-PET and QSM-MRI, respectively. &#x0201c;&#x02713;&#x0201d; indicates that the respective biomarker has been reported in humans with a range of neurological disorders as compared to healthy controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CNS Disorder</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">BGHM</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">BIA</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Addiction (alcohol and heroin)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B14-pharmaceuticals-18-00271" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceuticals-18-00271" ref-type="bibr">15</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B16-pharmaceuticals-18-00271" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceuticals-18-00271" ref-type="bibr">17</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Amyotrophic lateral sclerosis</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B18-pharmaceuticals-18-00271" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B19-pharmaceuticals-18-00271" ref-type="bibr">19</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Alzheimer&#x02019;s disease</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B6-pharmaceuticals-18-00271" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B6-pharmaceuticals-18-00271" ref-type="bibr">6</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Corticobasal degeneration</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B6-pharmaceuticals-18-00271" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Insufficient literature [<xref rid="B20-pharmaceuticals-18-00271" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Dementia with Lewy Bodies </td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B21-pharmaceuticals-18-00271" ref-type="bibr">21</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Insufficient literature [<xref rid="B22-pharmaceuticals-18-00271" ref-type="bibr">22</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Epilepsy</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B23-pharmaceuticals-18-00271" ref-type="bibr">23</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B24-pharmaceuticals-18-00271" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fronto-temporal dementia</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B25-pharmaceuticals-18-00271" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B26-pharmaceuticals-18-00271" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ischemic stroke</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B27-pharmaceuticals-18-00271" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Insufficient literature</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Multiple sclerosis</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B28-pharmaceuticals-18-00271" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B29-pharmaceuticals-18-00271" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Multiple system atrophy</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B30-pharmaceuticals-18-00271" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceuticals-18-00271" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B32-pharmaceuticals-18-00271" ref-type="bibr">32</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Parkinson&#x02019;s disease</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B6-pharmaceuticals-18-00271" ref-type="bibr">6</xref>,<xref rid="B33-pharmaceuticals-18-00271" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B6-pharmaceuticals-18-00271" ref-type="bibr">6</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Post-traumatic stress disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">Insufficient literature [<xref rid="B34-pharmaceuticals-18-00271" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceuticals-18-00271" ref-type="bibr">35</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Rat (insufficient lit.) [<xref rid="B36-pharmaceuticals-18-00271" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Progressive supranuclear palsy</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B37-pharmaceuticals-18-00271" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B38-pharmaceuticals-18-00271" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceuticals-18-00271" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Spinal cord injury</td><td align="center" valign="middle" rowspan="1" colspan="1">Neuropathic pain post-SCI [<xref rid="B40-pharmaceuticals-18-00271" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceuticals-18-00271" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Insufficient literature</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Spinocerebellar ataxia 3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B42-pharmaceuticals-18-00271" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B43-pharmaceuticals-18-00271" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Traumatic brain injury </td><td align="center" valign="middle" rowspan="1" colspan="1">Insufficient literature [<xref rid="B44-pharmaceuticals-18-00271" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceuticals-18-00271" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B46-pharmaceuticals-18-00271" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vascular dementia</td><td align="center" valign="middle" rowspan="1" colspan="1">Insufficient literature</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02713; [<xref rid="B47-pharmaceuticals-18-00271" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vascular parkinsonism</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02713; [<xref rid="B48-pharmaceuticals-18-00271" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insufficient literature</td></tr></tbody></table></table-wrap><p>From <xref rid="pharmaceuticals-18-00271-t001" ref-type="table">Table 1</xref>, it is evident that BGHM and BIA contribute to neurological dysfunction in a wide range of CNS disorders, and treatments targeting these biomarkers may benefit a large population of patients.</p></sec><sec id="sec3-pharmaceuticals-18-00271"><title>3. BGHM and BIA Are Also Involved in Multiple Aspects of AD Pathology</title><sec id="sec3dot1-pharmaceuticals-18-00271"><title>3.1. Decreased Acetylcholine Signaling and NMDA</title><p>The two classes of drugs that are currently prescribed to patients diagnosed with AD are cholinesterase inhibitors and n-methyl d-aspartate (NMDA) antagonists [<xref rid="B49-pharmaceuticals-18-00271" ref-type="bibr">49</xref>]. It is hypothesized that a decrease in acetylcholine (ACh) binding to receptors can contribute to the memory loss characteristic of AD. Acetylcholinesterase inhibitors are prescribed to reduce the degradation of ACh, and these are effective in slowing down the loss of cognitive function. Free iron catalyzes Fenton chemistry, which increases the generation of reactive oxygen species (ROS), causing oxidative stress. Both free iron and free heme, which are elevated in the brain in AD, have been shown to inactivate the human brain muscarinic cholinergic receptor in vitro [<xref rid="B50-pharmaceuticals-18-00271" ref-type="bibr">50</xref>]. Therefore, BIA can contribute to the breakdown of cholinergic signaling. The other class of drugs prescribed for AD are NMDA antagonists. The overactivation of NMDA receptors leads to excessive Ca<sup>2+</sup> influx and, as a result, an overstimulation of glutamatergic neurons. Due to glutamate being excitatory, it results in excitotoxicity, synaptic dysfunction, and neuronal cell death. Insulin receptors have been identified on glutamatergic neurons. Insulin potentiates NMDA receptors in neurons and, as a result, plays a role in synaptic transmission and plasticity and in long-term potentiation.</p></sec><sec id="sec3dot2-pharmaceuticals-18-00271"><title>3.2. Hyperphosphorylated Tau</title><p>Hyperphosphorylated tau (pTau) is a major research focus in the field of AD treatment. On accumulation, pTau forms neurofibrillary tangles, the progression of which has been shown to have a strong correlation with disease severity and memory loss [<xref rid="B5-pharmaceuticals-18-00271" ref-type="bibr">5</xref>]. BIA and pTau pathways are linked via glycogen synthase kinase 3&#x003b2; (GSK3&#x003b2;), an enzyme that phosphorylates tau. Deferoxamine, an iron chelator, has been demonstrated to decrease the activity of GSK3&#x003b2;, and the inhibition of GSK3&#x003b2; leads to a repression of tau hyperphosphorylation and blockage of tau deposition [<xref rid="B9-pharmaceuticals-18-00271" ref-type="bibr">9</xref>]. GSK3&#x003b2; is also downregulated in response to insulin [<xref rid="B51-pharmaceuticals-18-00271" ref-type="bibr">51</xref>].</p></sec><sec id="sec3dot3-pharmaceuticals-18-00271"><title>3.3. Amyloid Beta</title><p>For many years, the prevailing amyloid hypothesis was that accumulation of amyloid beta (A&#x003b2;) and its subsequent formation of extracellular plaques leads to brain cell death in AD [<xref rid="B2-pharmaceuticals-18-00271" ref-type="bibr">2</xref>]. A 2015 paper summarized some of the main reasons for looking beyond the amyloid hypothesis in treating AD [<xref rid="B52-pharmaceuticals-18-00271" ref-type="bibr">52</xref>]. This paper mentions that the A&#x003b2; hypothesis is much better at explaining the heritable early-onset AD and extrapolating it to explain sporadic AD is likely incorrect. Therefore, this might be one of the primary reasons that treating sporadic AD (which makes up over 95% of AD cases) with treatments targeting A&#x003b2; does not lead to amelioration of AD symptoms.</p><p>The uptake and metabolism of glucose in many brain regions is dependent on the presence of insulin, and insulin signaling triggers the release of the insulin-degrading enzyme (IDE) in microglia and neurons. IDE is not only involved in degrading insulin but also in degrading A&#x003b2;, so reduced insulin signaling that can result in BGHM, can also result in reduced A-beta degradation. Further, both free iron and heme are elevated in the brains of people with AD [<xref rid="B53-pharmaceuticals-18-00271" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceuticals-18-00271" ref-type="bibr">54</xref>]. Heme has been shown to form an A-beta-heme complex which has peroxidase activity [<xref rid="B55-pharmaceuticals-18-00271" ref-type="bibr">55</xref>].</p></sec><sec id="sec3dot4-pharmaceuticals-18-00271"><title>3.4. Neuroinflammation</title><p>Inflammation is another of the major contributors to brain tissue atrophy observed in AD. The abnormal accumulation of iron in the CNS, which contributes to neuroinflammation, has been suggested to occur early in the course of neurological disorders [<xref rid="B56-pharmaceuticals-18-00271" ref-type="bibr">56</xref>]. The activation of brain immune cells such as microglia and astrocytes is the primary cause of inflammation, and changes in the activation profile of microglia and increased release of inflammatory cytokines are thought to induce insulin resistance [<xref rid="B57-pharmaceuticals-18-00271" ref-type="bibr">57</xref>]. As described previously, BIA can cause a disruption in redox homeostasis and lead to increased spread of ROS, ultimately leading to oxidative damage and neuroinflammation. Iron chelators such as deferoxamine are known to have anti-inflammatory effects. Additionally, intranasal insulin is anti-inflammatory [<xref rid="B9-pharmaceuticals-18-00271" ref-type="bibr">9</xref>]. Therefore, treating BGHM with insulin can also alleviate neuroinflammation, as insulin reduces inflammation by regulating the activation of the NLRP3 inflammasome [<xref rid="B58-pharmaceuticals-18-00271" ref-type="bibr">58</xref>].</p></sec></sec><sec id="sec4-pharmaceuticals-18-00271"><title>4. Therapeutics Targeting BGHM or BIA</title><sec id="sec4dot1-pharmaceuticals-18-00271"><title>4.1. Intranasal Insulin for BGHM, Intranasal Deferoxamine (DFO) for BIA, and Other Intranasal Treatments for CNS Disorders</title><p>One of the major challenges with administering and targeting therapeutics to the brain has been the inability to deliver a wide range of active pharmaceutical ingredients and biologics to the brain due to the high selectivity of the blood&#x02013;brain barrier. Some therapeutics can act not only on the brain but also on other organs, which could result in unwanted systemic side effects. However, the discovery of the intranasal (IN) method of administering therapeutics to the upper third of the nasal cavity to bypass the blood&#x02013;brain barrier and target the brain via the olfactory and trigeminal neural pathways has demonstrated the possibility of delivering and targeting a wide variety of therapeutics to the brain to treat CNS disorders [<xref rid="B34-pharmaceuticals-18-00271" ref-type="bibr">34</xref>,<xref rid="B59-pharmaceuticals-18-00271" ref-type="bibr">59</xref>,<xref rid="B60-pharmaceuticals-18-00271" ref-type="bibr">60</xref>]. Here, we discuss the potential of repurposing two drugs approved for use in humans, insulin and deferoxamine, as therapeutics for CNS disorders.</p><p>Intranasal insulin (INI) has been demonstrated to safely improve memory in 20 min after administration in a clinical trial of human AD patients, and over a 21-day period, it improved memory in AD patients [<xref rid="B61-pharmaceuticals-18-00271" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceuticals-18-00271" ref-type="bibr">62</xref>]. Intranasal insulin also improved memory in patients with Type 2 Diabetes, a disease that doubles the risk for AD [<xref rid="B63-pharmaceuticals-18-00271" ref-type="bibr">63</xref>]. The treatment has also been effective at decreasing the progression of white matter hyperintensities that are observed in higher volumes in AD, although no improvement in memory was observed in this clinical trial [<xref rid="B64-pharmaceuticals-18-00271" ref-type="bibr">64</xref>]. In multiple clinical trials conducted with cognitively normal adults, intranasal insulin also safely improved memory without altering blood levels of insulin or glucose [<xref rid="B65-pharmaceuticals-18-00271" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceuticals-18-00271" ref-type="bibr">66</xref>].</p><p>INI acts on multiple pathways. Insulin promotes the uptake of glucose by brain cells by allowing transport of the GLUT 4 receptor to the cell surface. A 31P-MRI study showed that intranasal insulin administration increased energy (ATP and phosphocreatine) in brain cells in normal healthy humans [<xref rid="B67-pharmaceuticals-18-00271" ref-type="bibr">67</xref>]. Intranasal treatment of the intracerebroventricular-streptozotocin (ICV-STZ)-induced mouse model of Alzheimer&#x02019;s disease with the insulin sensitizer metformin improved learning and memory without altering the blood levels of glucose [<xref rid="B68-pharmaceuticals-18-00271" ref-type="bibr">68</xref>]. As stated before, the presence of insulin increases the production of insulin-degrading enzyme, which plays a role in degrading amyloid beta, a biomarker that has extensively been used to characterize the disease.</p><p>A clinical trial demonstrated the safety and efficacy of INI in PD [<xref rid="B69-pharmaceuticals-18-00271" ref-type="bibr">69</xref>]. Intranasal insulin improved verbal fluency and movement while reducing physical disability when compared to the control group treated with placebo [<xref rid="B69-pharmaceuticals-18-00271" ref-type="bibr">69</xref>]. A 2021 study found that INI improves mitochondrial function and ameliorates motor deficits in the 6-OHDA rat model of PD [<xref rid="B70-pharmaceuticals-18-00271" ref-type="bibr">70</xref>]. It is clear that more research is needed to understand the benefit of INI in many of the mentioned CNS disorders, especially given that <xref rid="pharmaceuticals-18-00271-t001" ref-type="table">Table 1</xref> shows that BGHM has been observed in these diseases. In summary, intranasal insulin safely bypasses the blood&#x02013;brain barrier, increases brain cell energy, reduces inflammation, attenuates the HPA axis response to stress, improves memory, and reduces white matter hyperintensity in Alzheimer&#x02019;s without altering the blood levels of insulin or glucose [<xref rid="B58-pharmaceuticals-18-00271" ref-type="bibr">58</xref>,<xref rid="B64-pharmaceuticals-18-00271" ref-type="bibr">64</xref>,<xref rid="B67-pharmaceuticals-18-00271" ref-type="bibr">67</xref>,<xref rid="B71-pharmaceuticals-18-00271" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceuticals-18-00271" ref-type="bibr">72</xref>]. Intranasal insulin also causes improvements in T2D, Parkinson&#x02019;s, and healthy adults in clinical trials, and is a potential treatment for TBI, SCI, PTSD, and certain other CNS disorders (see <xref rid="pharmaceuticals-18-00271-t002" ref-type="table">Table 2</xref>) [<xref rid="B63-pharmaceuticals-18-00271" ref-type="bibr">63</xref>,<xref rid="B65-pharmaceuticals-18-00271" ref-type="bibr">65</xref>,<xref rid="B69-pharmaceuticals-18-00271" ref-type="bibr">69</xref>].</p><p>Intranasal iron chelators also have significant therapeutic potential as they can bind free iron in the brain, effectively aiding in reducing oxidative stress and ferroptosis. One such iron chelator that has been tested in AD is deferoxamine (DFO). In 2012, it was demonstrated that APP/PS1 mice treated with IN DFO showed reduced spatial memory loss in the Morris water maze, and IN DFO was shown to reverse iron-induced memory loss in the same mouse model in 2013 [<xref rid="B73-pharmaceuticals-18-00271" ref-type="bibr">73</xref>,<xref rid="B74-pharmaceuticals-18-00271" ref-type="bibr">74</xref>]. Improved performance in radial arm water maze was also observed in P301L mice, a model for tauopathy [<xref rid="B75-pharmaceuticals-18-00271" ref-type="bibr">75</xref>]. In the streptozotocin rat model of AD, mice treated with IN DFO performed significantly better in Morris water maze and tapered balance beam test, demonstrating better spatial memory and fine motor control [<xref rid="B76-pharmaceuticals-18-00271" ref-type="bibr">76</xref>]. A 2020 study revealed that IN DFO showed improved memory in cognitively normal C57 mice [<xref rid="B77-pharmaceuticals-18-00271" ref-type="bibr">77</xref>]. Given the potential of IN DFO in treating mouse models of Alzheimer&#x02019;s disease, future clinical trials will be beneficial in fully understanding its utility in treating AD. IN DFO has also been shown to be effective in treating rodent models of ischemic stroke and PD (<xref rid="pharmaceuticals-18-00271-t002" ref-type="table">Table 2</xref>). However, as seen from <xref rid="pharmaceuticals-18-00271-t001" ref-type="table">Table 1</xref> and <xref rid="pharmaceuticals-18-00271-t002" ref-type="table">Table 2</xref>, many CNS disorders that have shown BIA are yet to be explored to understand if IN DFO administration can ameliorate the symptoms of the disease.</p><p>In humans, the safety and efficacy of DFO were first assessed in 1991, in a clinical trial of intramuscular desferrioxamine (deferoxamine) in individuals with probable AD. The study reported that the treatment resulted in a significantly lower rate of decline of daily living skills compared to the no-treatment group, and the no-treatment group showed a twice-as-rapid mean rate of decline [<xref rid="B78-pharmaceuticals-18-00271" ref-type="bibr">78</xref>]. The primary side effects reported by this study were loss of appetite and weight. In 1989, a small study in humans with iron overload secondary to chronic transfusion therapy reported that treatment with high doses of IN DFO in these individuals resulted in few side effects, mainly mild nasal irritation and an unpleasant taste in the mouth [<xref rid="B79-pharmaceuticals-18-00271" ref-type="bibr">79</xref>]. Carefully designed and controlled clinical trials will be needed to assess the safety and efficacy of intranasal deferoxamine in patients with CNS disorders.</p><table-wrap position="anchor" id="pharmaceuticals-18-00271-t002"><object-id pub-id-type="pii">pharmaceuticals-18-00271-t002_Table 2</object-id><label>Table 2</label><caption><p>Evidence for the benefit of treating BGHM with INI or BIA with IN DFO in a range of neurological disorders tested in specific animal models. &#x0201c;Potentially&#x0201d; indicates that there is research hypothesizing that the treatment will be beneficial.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CNS Disorder</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Evidence for Benefit of INI</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Evidence for Benefit of IN DFO</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Alzheimer&#x02019;s disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Human [<xref rid="B61-pharmaceuticals-18-00271" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceuticals-18-00271" ref-type="bibr">62</xref>,<xref rid="B65-pharmaceuticals-18-00271" ref-type="bibr">65</xref>,<xref rid="B80-pharmaceuticals-18-00271" ref-type="bibr">80</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Mouse [<xref rid="B76-pharmaceuticals-18-00271" ref-type="bibr">76</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Epilepsy</td><td align="center" valign="middle" rowspan="1" colspan="1">Mouse [<xref rid="B81-pharmaceuticals-18-00271" ref-type="bibr">81</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">No literature</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Frontotemporal dementia</td><td align="center" valign="middle" rowspan="1" colspan="1">No literature</td><td align="center" valign="middle" rowspan="1" colspan="1">Mouse [<xref rid="B75-pharmaceuticals-18-00271" ref-type="bibr">75</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ischemic stroke</td><td align="center" valign="middle" rowspan="1" colspan="1">Potentially [<xref rid="B82-pharmaceuticals-18-00271" ref-type="bibr">82</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Rat [<xref rid="B83-pharmaceuticals-18-00271" ref-type="bibr">83</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Parkinson&#x02019;s disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Human [<xref rid="B69-pharmaceuticals-18-00271" ref-type="bibr">69</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Rat [<xref rid="B84-pharmaceuticals-18-00271" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Post-traumatic stress disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">Potentially [<xref rid="B85-pharmaceuticals-18-00271" ref-type="bibr">85</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Potentially [<xref rid="B36-pharmaceuticals-18-00271" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Spinal cord injury</td><td align="center" valign="middle" rowspan="1" colspan="1">Potentially (rat) [<xref rid="B86-pharmaceuticals-18-00271" ref-type="bibr">86</xref>,<xref rid="B87-pharmaceuticals-18-00271" ref-type="bibr">87</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Rat [<xref rid="B88-pharmaceuticals-18-00271" ref-type="bibr">88</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Traumatic brain injury </td><td align="center" valign="middle" rowspan="1" colspan="1">Rat [<xref rid="B89-pharmaceuticals-18-00271" ref-type="bibr">89</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">No literature</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vascular dementia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rat [<xref rid="B90-pharmaceuticals-18-00271" ref-type="bibr">90</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Potentially [<xref rid="B91-pharmaceuticals-18-00271" ref-type="bibr">91</xref>]</td></tr></tbody></table></table-wrap><p>Thus far, no one has published results for the effects of INI or IN DFO in the following disorders in humans or animal models: addiction, dementia with Lewy bodies, vascular parkinsonism, progressive supranuclear palsy, corticobasal degeneration, amyotrophic lateral sclerosis, spinocerebellar ataxia 3 and multiple sclerosis. However, as shown in <xref rid="pharmaceuticals-18-00271-t001" ref-type="table">Table 1</xref>, many of these disorders exhibit BGHM and/or BIA providing a rationale for testing the safety and efficacy of INI and/or IN DFO.</p></sec><sec id="sec4dot2-pharmaceuticals-18-00271"><title>4.2. Insulin-Modulating Drugs: Metformin, Thiazolidinediones, Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1</title><p>Recent studies have demonstrated many insulin-modulating drugs to have efficacy in treating AD [<xref rid="B92-pharmaceuticals-18-00271" ref-type="bibr">92</xref>].</p><p>Metformin, one of the primary insulin-sensitizing medications prescribed to patients with Type 2 Diabetes Mellitus (T2DM), improved memory in patients with AD and no history of diabetes or pre-diabetes [<xref rid="B93-pharmaceuticals-18-00271" ref-type="bibr">93</xref>]. Pioglitazone, a member of the class of medications known as thiazolidinediones, has also been shown to improve dementia in patients with AD [<xref rid="B94-pharmaceuticals-18-00271" ref-type="bibr">94</xref>]. A 2020 paper found that sodium-glucose cotransporter-2 (SGLT-2) antagonist Empagliflozin reduced vascular damage and cognitive impairment in AD-T2D mice showing potential for treatment [<xref rid="B95-pharmaceuticals-18-00271" ref-type="bibr">95</xref>]. Glucagon-like peptide-1 (GLP-1) receptor agonists are a family of drugs that are used in the treatment of T2DM, and use of these has shown benefit in treating pathologies of AD and PD in phase II clinical trials [<xref rid="B96-pharmaceuticals-18-00271" ref-type="bibr">96</xref>]. A recent study targeted both BGHM and BIA in a mouse model of PD using a treatment that contained a GLP-1 receptor agonist, Exendin-4, and the iron chelator DFO [<xref rid="B97-pharmaceuticals-18-00271" ref-type="bibr">97</xref>]. The study reported that intranasally administered nanoparticles loaded with Exendin-4 peptide-conjugated DFO, synergistically ameliorated dopamine neuron loss and neuroinflammation in the substantia nigra and motor deficits in the mice. Future studies testing the effectiveness of these treatments in diseases other than AD and PD can help to determine the CNS disorders that may benefit from these treatments.</p></sec></sec><sec id="sec5-pharmaceuticals-18-00271"><title>5. Limitations and Future Directions</title><p>Clinical trials of INI to date have not revealed major adverse side effects (<xref rid="sec4dot1-pharmaceuticals-18-00271" ref-type="sec">Section 4.1</xref>). However, because brain glucose hypermetabolism has been observed in certain brain regions of some neurological disorders, it will be important to determine if the presence of hypermetabolism in those brain regions is a contraindication to the treatment of BGHM in other brain regions [<xref rid="B18-pharmaceuticals-18-00271" ref-type="bibr">18</xref>]. Insulins designed for use in treating diabetes contain preservatives, which may be responsible for the mild nasal irritation reported by some participants in clinical trials. Elimination of the need for preservatives by creating unit dose nasal sprays or by other means could help to alleviate this problem.</p><p>There is a need for clinical trials assessing the safety and efficacy of therapeutics targeting BGHM and BIA in the neurological disorders discussed in <xref rid="pharmaceuticals-18-00271-t001" ref-type="table">Table 1</xref>. In addition, assessing the efficacy of agents targeting BGHM in combination with agents targeting BIA for additive or synergistic effects is essential.</p></sec><sec sec-type="conclusions" id="sec6-pharmaceuticals-18-00271"><title>6. Conclusions</title><p>BGHM and BIA are promising therapeutic targets beyond their utility in monitoring disease progression or in contributing to distinguishing various CNS disorders based on brain biodistribution of the biomarkers. BGHM and BIA are observed across a large range of CNS disorders, and treatments targeting them have demonstrated therapeutic potential in preclinical studies and for intranasal insulin in clinical trials for AD and PD. With more experimental evidence and clinical trials demonstrating safety and efficacy, these treatments can also be repurposed to treat other CNS disorders that show BGHM and/or BIA.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization: I.Y.R. and W.H.F.II; outline and format: I.Y.R., W.H.F.II and L.R.H.; writing&#x02014;original draft: I.Y.R. and W.H.F.II; writing&#x02014;review and editing: I.Y.R., W.H.F.II and L.R.H. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>W.H.F.II and L.R.H. are inventors on patents owned by the HealthPartners Institute related to intranasal insulin and intranasal deferoxamine. I.Y.R. has no competing interests.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">BGHM</td><td align="left" valign="middle" rowspan="1" colspan="1">Brain glucose hypometabolism</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BIA</td><td align="left" valign="middle" rowspan="1" colspan="1">Brain iron accumulation</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AD</td><td align="left" valign="middle" rowspan="1" colspan="1">Alzheimer&#x02019;s disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CNS</td><td align="left" valign="middle" rowspan="1" colspan="1">Central Nervous System</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ROS</td><td align="left" valign="middle" rowspan="1" colspan="1">Reactive oxygen species</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FDG-PET</td><td align="left" valign="middle" rowspan="1" colspan="1">Fluorodeoxyglucose positron emission tomography</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QSM-MRI</td><td align="left" valign="middle" rowspan="1" colspan="1">Quantitative susceptibility mapping magnetic resonance imaging</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NMDA</td><td align="left" valign="middle" rowspan="1" colspan="1">N-methyl d-aspartate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ACh</td><td align="left" valign="middle" rowspan="1" colspan="1">Acetylcholine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">pTau</td><td align="left" valign="middle" rowspan="1" colspan="1">Hyperphosphorylated tau</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GSK3&#x003b2;</td><td align="left" valign="middle" rowspan="1" colspan="1">Glycogen synthase kinase 3&#x003b2;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">A&#x003b2;</td><td align="left" valign="middle" rowspan="1" colspan="1">Amyloid beta</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IDE</td><td align="left" valign="middle" rowspan="1" colspan="1">Insulin-degrading enzyme</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IN</td><td align="left" valign="middle" rowspan="1" colspan="1">Intranasal </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">INI</td><td align="left" valign="middle" rowspan="1" colspan="1">Intranasal insulin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DFO</td><td align="left" valign="middle" rowspan="1" colspan="1">Deferoxamine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TBI</td><td align="left" valign="middle" rowspan="1" colspan="1">Traumatic brain injury</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SCI</td><td align="left" valign="middle" rowspan="1" colspan="1">Spinal cord injury</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PTSD</td><td align="left" valign="middle" rowspan="1" colspan="1">Post-traumatic stress disorder</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GLP-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Glucagon-Like Peptide-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T2DM</td><td align="left" valign="middle" rowspan="1" colspan="1">Type 2 Diabetes Mellitus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SGLT-2</td><td align="left" valign="middle" rowspan="1" colspan="1">Sodium-glucose cotransporter-2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PD</td><td align="left" valign="middle" rowspan="1" colspan="1">Parkinson&#x02019;s disease</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00271"><label>1.</label><element-citation publication-type="journal"><article-title>2024 Alzheimer&#x02019;s Disease Facts and Figures</article-title><source>Alzheimer&#x02019;s Dement.</source><year>2024</year><volume>20</volume><fpage>3708</fpage><lpage>3821</lpage><pub-id pub-id-type="doi">10.1002/alz.13809</pub-id><pub-id pub-id-type="pmid">38689398</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-18-00271"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>B.</given-names></name>
<name><surname>Ownby</surname><given-names>R.L.</given-names></name>
</person-group><article-title>Disease-Modifying Treatments and Their Future in Alzheimer&#x02019;s Disease Management</article-title><source>Cureus</source><year>2024</year><volume>16</volume><fpage>e56105</fpage><pub-id pub-id-type="doi">10.7759/cureus.56105</pub-id><pub-id pub-id-type="pmid">38618323</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-18-00271"><label>3.</label><element-citation publication-type="webpage"><article-title>The Amyloid Hypothesis of Alzheimer&#x02019;s Disease at 25 Years&#x02014;PubMed</article-title><comment>Available online: <ext-link xlink:href="https://pubmed-ncbi-nlm-nih-gov.ezp3.lib.umn.edu/27025652/" ext-link-type="uri">https://pubmed-ncbi-nlm-nih-gov.ezp3.lib.umn.edu/27025652/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-15">(accessed on 15 February 2023)</date-in-citation></element-citation></ref><ref id="B4-pharmaceuticals-18-00271"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Espay</surname><given-names>A.J.</given-names></name>
<name><surname>Kepp</surname><given-names>K.P.</given-names></name>
<name><surname>Herrup</surname><given-names>K.</given-names></name>
</person-group><article-title>Lecanemab and Donanemab as Therapies for Alzheimer&#x02019;s Disease: An Illustrated Perspective on the Data</article-title><source>eNeuro</source><year>2024</year><volume>11</volume><fpage>ENEURO.0319-23.2024</fpage><pub-id pub-id-type="doi">10.1523/ENEURO.0319-23.2024</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-18-00271"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brier</surname><given-names>M.R.</given-names></name>
<name><surname>Gordon</surname><given-names>B.</given-names></name>
<name><surname>Friedrichsen</surname><given-names>K.</given-names></name>
<name><surname>McCarthy</surname><given-names>J.</given-names></name>
<name><surname>Stern</surname><given-names>A.</given-names></name>
<name><surname>Christensen</surname><given-names>J.</given-names></name>
<name><surname>Owen</surname><given-names>C.</given-names></name>
<name><surname>Aldea</surname><given-names>P.</given-names></name>
<name><surname>Su</surname><given-names>Y.</given-names></name>
<name><surname>Hassenstab</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Tau and A&#x003b2; Imaging, CSF Measures, and Cognition in Alzheimer&#x02019;s Disease</article-title><source>Sci. Transl. Med.</source><year>2016</year><volume>8</volume><fpage>ra66</fpage><lpage>ra338</lpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf2362</pub-id></element-citation></ref><ref id="B6-pharmaceuticals-18-00271"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rao</surname><given-names>I.Y.</given-names></name>
<name><surname>Hanson</surname><given-names>L.R.</given-names></name>
<name><surname>Johnson</surname><given-names>J.C.</given-names></name>
<name><surname>Rosenbloom</surname><given-names>M.H.</given-names></name>
<name><surname>Frey</surname><given-names>W.H.</given-names></name>
</person-group><article-title>Brain Glucose Hypometabolism and Iron Accumulation in Different Brain Regions in Alzheimer&#x02019;s and Parkinson&#x02019;s Diseases</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><elocation-id>551</elocation-id><pub-id pub-id-type="doi">10.3390/ph15050551</pub-id><pub-id pub-id-type="pmid">35631378</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-18-00271"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raichle</surname><given-names>M.E.</given-names></name>
<name><surname>Gusnard</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Appraising the Brain&#x02019;s Energy Budget</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2002</year><volume>99</volume><fpage>10237</fpage><lpage>10239</lpage><pub-id pub-id-type="doi">10.1073/pnas.172399499</pub-id><pub-id pub-id-type="pmid">12149485</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-18-00271"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pivovarova</surname><given-names>O.</given-names></name>
<name><surname>H&#x000f6;hn</surname><given-names>A.</given-names></name>
<name><surname>Grune</surname><given-names>T.</given-names></name>
<name><surname>Pfeiffer</surname><given-names>A.F.H.</given-names></name>
<name><surname>Rudovich</surname><given-names>N.</given-names></name>
</person-group><article-title>Insulin-Degrading Enzyme: New Therapeutic Target for Diabetes and Alzheimer&#x02019;s Disease?</article-title><source>Ann. Med.</source><year>2016</year><volume>48</volume><fpage>614</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1080/07853890.2016.1197416</pub-id><pub-id pub-id-type="pmid">27320287</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-18-00271"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kosyakovsky</surname><given-names>J.</given-names></name>
<name><surname>Fine</surname><given-names>J.M.</given-names></name>
<name><surname>Frey</surname><given-names>W.H.</given-names></name>
<name><surname>Hanson</surname><given-names>L.R.</given-names></name>
</person-group><article-title>Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease</article-title><source>Pharmaceuticals</source><year>2021</year><volume>14</volume><elocation-id>95</elocation-id><pub-id pub-id-type="doi">10.3390/ph14020095</pub-id><pub-id pub-id-type="pmid">33513737</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-18-00271"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cabantchik</surname><given-names>Z.I.</given-names></name>
</person-group><article-title>Labile Iron in Cells and Body Fluids: Physiology, Pathology, and Pharmacology</article-title><source>Front. Pharmacol.</source><year>2014</year><volume>5</volume><elocation-id>45</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2014.00045</pub-id><pub-id pub-id-type="pmid">24659969</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-18-00271"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Belaidi</surname><given-names>A.A.</given-names></name>
<name><surname>Bush</surname><given-names>A.I.</given-names></name>
</person-group><article-title>Iron Neurochemistry in Alzheimer&#x02019;s Disease and Parkinson&#x02019;s Disease: Targets for Therapeutics</article-title><source>J. Neurochem.</source><year>2016</year><volume>139</volume><fpage>179</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1111/jnc.13425</pub-id></element-citation></ref><ref id="B12-pharmaceuticals-18-00271"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dixon</surname><given-names>S.J.</given-names></name>
<name><surname>Lemberg</surname><given-names>K.M.</given-names></name>
<name><surname>Lamprecht</surname><given-names>M.R.</given-names></name>
<name><surname>Skouta</surname><given-names>R.</given-names></name>
<name><surname>Zaitsev</surname><given-names>E.M.</given-names></name>
<name><surname>Gleason</surname><given-names>C.E.</given-names></name>
<name><surname>Patel</surname><given-names>D.N.</given-names></name>
<name><surname>Bauer</surname><given-names>A.J.</given-names></name>
<name><surname>Cantley</surname><given-names>A.M.</given-names></name>
<name><surname>Yang</surname><given-names>W.S.</given-names></name>
<etal/>
</person-group><article-title>Ferroptosis: An Iron-Dependent Form of Non-Apoptotic Cell Death</article-title><source>Cell</source><year>2012</year><volume>149</volume><fpage>1060</fpage><lpage>1072</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.03.042</pub-id><pub-id pub-id-type="pmid">22632970</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-18-00271"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jakaria</surname><given-names>M.</given-names></name>
<name><surname>Belaidi</surname><given-names>A.A.</given-names></name>
<name><surname>Bush</surname><given-names>A.I.</given-names></name>
<name><surname>Ayton</surname><given-names>S.</given-names></name>
</person-group><article-title>Ferroptosis as a Mechanism of Neurodegeneration in Alzheimer&#x02019;s Disease</article-title><source>J. Neurochem.</source><year>2021</year><volume>159</volume><fpage>804</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1111/jnc.15519</pub-id><pub-id pub-id-type="pmid">34553778</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-18-00271"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bralet</surname><given-names>M.-C.</given-names></name>
<name><surname>Mitelman</surname><given-names>S.A.</given-names></name>
<name><surname>Goodman</surname><given-names>C.R.</given-names></name>
<name><surname>Lincoln</surname><given-names>S.</given-names></name>
<name><surname>Hazlett</surname><given-names>E.A.</given-names></name>
<name><surname>Buchsbaum</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Fluorodeoxyglucose Positron Emission Tomography Scans in Patients with Alcohol Use Disorder</article-title><source>Alcohol. Clin. Exp. Res.</source><year>2022</year><volume>46</volume><fpage>994</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1111/acer.14845</pub-id><pub-id pub-id-type="pmid">35451074</pub-id>
</element-citation></ref><ref id="B15-pharmaceuticals-18-00271"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jin</surname><given-names>L.</given-names></name>
<name><surname>Yuan</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Wei</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Wei</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Abnormal Cerebral Metabolism and Metabolic Connectivity in Individuals with Heroin Dependence: An Integrated Resting-State PET/fMRI Study in Large-Scale Networks</article-title><source>J. Psychiatry Neurosci.</source><year>2023</year><volume>48</volume><fpage>E295</fpage><lpage>E304</lpage><pub-id pub-id-type="doi">10.1503/jpn.220171</pub-id><pub-id pub-id-type="pmid">37437921</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-18-00271"><label>16.</label><element-citation publication-type="confproc"><person-group person-group-type="author">
<name><surname>Wei</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Wei</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Cheng</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Quantitative Susceptibility Mapping for Drug-Addicted Human Brain</article-title><source>Proceedings of the 2018 14th IEEE International Conference on Signal Processing (ICSP)</source><conf-loc>Beijing, China</conf-loc><conf-date>12&#x02013;16 August 2018</conf-date><publisher-name>IEEE</publisher-name><publisher-loc>Beijing, China</publisher-loc><fpage>1184</fpage><lpage>1188</lpage></element-citation></ref><ref id="B17-pharmaceuticals-18-00271"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>H.</given-names></name>
<name><surname>Hubertus</surname><given-names>S.</given-names></name>
<name><surname>Thomas</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>A.M.</given-names></name>
<name><surname>Gerhardt</surname><given-names>S.</given-names></name>
<name><surname>Gerchen</surname><given-names>M.F.</given-names></name>
<name><surname>Sommer</surname><given-names>W.H.</given-names></name>
<name><surname>Kiefer</surname><given-names>F.</given-names></name>
<name><surname>Schad</surname><given-names>L.</given-names></name>
<name><surname>Vollst&#x000e4;dt-Klein</surname><given-names>S.</given-names></name>
</person-group><article-title>Association between Iron Accumulation in the Dorsal Striatum and Compulsive Drinking in Alcohol Use Disorder</article-title><source>Psychopharmacology</source><year>2023</year><volume>240</volume><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1007/s00213-022-06301-7</pub-id><pub-id pub-id-type="pmid">36577866</pub-id>
</element-citation></ref><ref id="B18-pharmaceuticals-18-00271"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tefera</surname><given-names>T.W.</given-names></name>
<name><surname>Steyn</surname><given-names>F.J.</given-names></name>
<name><surname>Ngo</surname><given-names>S.T.</given-names></name>
<name><surname>Borges</surname><given-names>K.</given-names></name>
</person-group><article-title>CNS Glucose Metabolism in Amyotrophic Lateral Sclerosis: A Therapeutic Target?</article-title><source>Cell Biosci.</source><year>2021</year><volume>11</volume><elocation-id>14</elocation-id><pub-id pub-id-type="doi">10.1186/s13578-020-00511-2</pub-id><pub-id pub-id-type="pmid">33431046</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-18-00271"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhattarai</surname><given-names>A.</given-names></name>
<name><surname>Egan</surname><given-names>G.F.</given-names></name>
<name><surname>Talman</surname><given-names>P.</given-names></name>
<name><surname>Chua</surname><given-names>P.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
</person-group><article-title>Magnetic Resonance Iron Imaging in Amyotrophic Lateral Sclerosis</article-title><source>J. Magn. Reson. Imaging</source><year>2022</year><volume>55</volume><fpage>1283</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1002/jmri.27530</pub-id><pub-id pub-id-type="pmid">33586315</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-18-00271"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miyata</surname><given-names>M.</given-names></name>
<name><surname>Kakeda</surname><given-names>S.</given-names></name>
<name><surname>Toyoshima</surname><given-names>Y.</given-names></name>
<name><surname>Ide</surname><given-names>S.</given-names></name>
<name><surname>Okada</surname><given-names>K.</given-names></name>
<name><surname>Adachi</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Korogi</surname><given-names>Y.</given-names></name>
</person-group><article-title>Potential Usefulness of Signal Intensity of Cerebral Gyri on Quantitative Susceptibility Mapping for Discriminating Corticobasal Degeneration from Progressive Supranuclear Palsy and Parkinson&#x02019;s Disease</article-title><source>Neuroradiology</source><year>2019</year><volume>61</volume><fpage>1251</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.1007/s00234-019-02253-6</pub-id><pub-id pub-id-type="pmid">31267152</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-18-00271"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caminiti</surname><given-names>S.P.</given-names></name>
<name><surname>Sala</surname><given-names>A.</given-names></name>
<name><surname>Iaccarino</surname><given-names>L.</given-names></name>
<name><surname>Beretta</surname><given-names>L.</given-names></name>
<name><surname>Pilotto</surname><given-names>A.</given-names></name>
<name><surname>Gianolli</surname><given-names>L.</given-names></name>
<name><surname>Iannaccone</surname><given-names>S.</given-names></name>
<name><surname>Magnani</surname><given-names>G.</given-names></name>
<name><surname>Padovani</surname><given-names>A.</given-names></name>
<name><surname>Ferini-Strambi</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Brain Glucose Metabolism in Lewy Body Dementia: Implications for Diagnostic Criteria</article-title><source>Alzheimers Res. Ther.</source><year>2019</year><volume>11</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/s13195-019-0473-4</pub-id><pub-id pub-id-type="pmid">30797240</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-18-00271"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Bal&#x000e1;&#x0017e;ov&#x000e1;</surname><given-names>Z.</given-names></name>
<name><surname>Nov&#x000e1;kov&#x000e1;</surname><given-names>M.</given-names></name>
<name><surname>Minsterov&#x000e1;</surname><given-names>A.</given-names></name>
<name><surname>Rektorov&#x000e1;</surname><given-names>I.</given-names></name>
</person-group><article-title>Chapter Four&#x02014;Structural and Functional Magnetic Resonance Imaging of Dementia With Lewy Bodies</article-title><source>International Review of Neurobiology</source><person-group person-group-type="editor">
<name><surname>Politis</surname><given-names>M.</given-names></name>
</person-group><comment>Imaging in Movement Disorders: Imaging in Non-Parkinsonian Movement Disorders and Dementias, Part 2</comment><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2019</year><volume>Volume 144</volume><fpage>95</fpage><lpage>141</lpage></element-citation></ref><ref id="B23-pharmaceuticals-18-00271"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boison</surname><given-names>D.</given-names></name>
<name><surname>Steinh&#x000e4;user</surname><given-names>C.</given-names></name>
</person-group><article-title>Epilepsy and Astrocyte Energy Metabolism</article-title><source>Glia</source><year>2018</year><volume>66</volume><fpage>1235</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1002/glia.23247</pub-id><pub-id pub-id-type="pmid">29044647</pub-id>
</element-citation></ref><ref id="B24-pharmaceuticals-18-00271"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Kuang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>M.</given-names></name>
<name><surname>Ma</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
</person-group><article-title>Iron Metabolism and Ferroptosis in Epilepsy</article-title><source>Front. Neurosci.</source><year>2020</year><volume>14</volume><elocation-id>601193</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2020.601193</pub-id><pub-id pub-id-type="pmid">33424539</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-18-00271"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garrett</surname><given-names>L.R.</given-names></name>
<name><surname>Niccoli</surname><given-names>T.</given-names></name>
</person-group><article-title>Frontotemporal Dementia and Glucose Metabolism</article-title><source>Front. Neurosci.</source><year>2022</year><volume>16</volume><elocation-id>812222</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2022.812222</pub-id><pub-id pub-id-type="pmid">35281504</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-18-00271"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sheelakumari</surname><given-names>R.</given-names></name>
<name><surname>Kesavadas</surname><given-names>C.</given-names></name>
<name><surname>Varghese</surname><given-names>T.</given-names></name>
<name><surname>Sreedharan</surname><given-names>R.M.</given-names></name>
<name><surname>Thomas</surname><given-names>B.</given-names></name>
<name><surname>Verghese</surname><given-names>J.</given-names></name>
<name><surname>Mathuranath</surname><given-names>P.S.</given-names></name>
</person-group><article-title>Assessment of Iron Deposition in the Brain in Frontotemporal Dementia and Its Correlation with Behavioral Traits</article-title><source>AJNR Am. J. Neuroradiol.</source><year>2017</year><volume>38</volume><fpage>1953</fpage><lpage>1958</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A5339</pub-id><pub-id pub-id-type="pmid">28838910</pub-id>
</element-citation></ref><ref id="B27-pharmaceuticals-18-00271"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nasu</surname><given-names>S.</given-names></name>
<name><surname>Hata</surname><given-names>T.</given-names></name>
<name><surname>Nakajima</surname><given-names>T.</given-names></name>
<name><surname>Suzuki</surname><given-names>Y.</given-names></name>
</person-group><article-title>[Evaluation of 18F-FDG PET in acute ischemic stroke: Assessment of hyper accumulation around the lesion]</article-title><source>Kaku Igaku</source><year>2002</year><volume>39</volume><fpage>103</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">12058418</pub-id>
</element-citation></ref><ref id="B28-pharmaceuticals-18-00271"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tepav&#x0010d;evi&#x00107;</surname><given-names>V.</given-names></name>
</person-group><article-title>Oligodendroglial Energy Metabolism and (Re)Myelination</article-title><source>Life</source><year>2021</year><volume>11</volume><elocation-id>238</elocation-id><pub-id pub-id-type="doi">10.3390/life11030238</pub-id><pub-id pub-id-type="pmid">33805670</pub-id>
</element-citation></ref><ref id="B29-pharmaceuticals-18-00271"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ropele</surname><given-names>S.</given-names></name>
<name><surname>Enzinger</surname><given-names>C.</given-names></name>
<name><surname>Fazekas</surname><given-names>F.</given-names></name>
</person-group><article-title>Iron Mapping in Multiple Sclerosis</article-title><source>Neuroimaging Clin. N. Am.</source><year>2017</year><volume>27</volume><fpage>335</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/j.nic.2016.12.003</pub-id><pub-id pub-id-type="pmid">28391790</pub-id>
</element-citation></ref><ref id="B30-pharmaceuticals-18-00271"><label>30.</label><element-citation publication-type="journal"><article-title>Abnormal Pattern of Brain Glucose Metabolism in Multiple System Atrophy</article-title><source>MDS Abstr.</source><year>2020</year><volume>35</volume><fpage>S114</fpage><lpage>S116</lpage></element-citation></ref><ref id="B31-pharmaceuticals-18-00271"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Ge</surname><given-names>J.-J.</given-names></name>
<name><surname>Lu</surname><given-names>J.-Y.</given-names></name>
<name><surname>Chen</surname><given-names>Q.-S.</given-names></name>
<name><surname>He</surname><given-names>S.-J.</given-names></name>
<name><surname>Li</surname><given-names>X.-Y.</given-names></name>
<name><surname>Zhao</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>Y.-M.</given-names></name>
<name><surname>Wu</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Cerebral Metabolism Related to Cognitive Impairments in Multiple System Atrophy</article-title><source>Front. Neurol.</source><year>2021</year><volume>12</volume><elocation-id>652059</elocation-id><pub-id pub-id-type="doi">10.3389/fneur.2021.652059</pub-id><pub-id pub-id-type="pmid">33868154</pub-id>
</element-citation></ref><ref id="B32-pharmaceuticals-18-00271"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lancione</surname><given-names>M.</given-names></name>
<name><surname>Cencini</surname><given-names>M.</given-names></name>
<name><surname>Costagli</surname><given-names>M.</given-names></name>
<name><surname>Donatelli</surname><given-names>G.</given-names></name>
<name><surname>Tosetti</surname><given-names>M.</given-names></name>
<name><surname>Giannini</surname><given-names>G.</given-names></name>
<name><surname>Zangaglia</surname><given-names>R.</given-names></name>
<name><surname>Calandra-Buonaura</surname><given-names>G.</given-names></name>
<name><surname>Pacchetti</surname><given-names>C.</given-names></name>
<name><surname>Cortelli</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Diagnostic Accuracy of Quantitative Susceptibility Mapping in Multiple System Atrophy: The Impact of Echo Time and the Potential of Histogram Analysis</article-title><source>NeuroImage Clin.</source><year>2022</year><volume>34</volume><fpage>102989</fpage><pub-id pub-id-type="doi">10.1016/j.nicl.2022.102989</pub-id><pub-id pub-id-type="pmid">35303599</pub-id>
</element-citation></ref><ref id="B33-pharmaceuticals-18-00271"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shin</surname><given-names>J.H.</given-names></name>
<name><surname>Shin</surname><given-names>S.A.</given-names></name>
<name><surname>Lee</surname><given-names>J.-Y.</given-names></name>
<name><surname>Nam</surname><given-names>H.</given-names></name>
<name><surname>Lim</surname><given-names>J.-S.</given-names></name>
<name><surname>Kim</surname><given-names>Y.K.</given-names></name>
</person-group><article-title>Precuneus Degeneration and Isolated Apathy in Patients with Parkinson&#x02019;s Disease</article-title><source>Neurosci. Lett.</source><year>2017</year><volume>653</volume><fpage>250</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2017.05.061</pub-id><pub-id pub-id-type="pmid">28579482</pub-id>
</element-citation></ref><ref id="B34-pharmaceuticals-18-00271"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hanson</surname><given-names>L.R.</given-names></name>
<name><surname>Frey</surname><given-names>W.H.</given-names></name>
</person-group><article-title>Intranasal Delivery Bypasses the Blood-Brain Barrier to Target Therapeutic Agents to the Central Nervous System and Treat Neurodegenerative Disease</article-title><source>BMC Neurosci.</source><year>2008</year><volume>9</volume><elocation-id>S5</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2202-9-S3-S5</pub-id><pub-id pub-id-type="pmid">19091002</pub-id>
</element-citation></ref><ref id="B35-pharmaceuticals-18-00271"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soncin</surname><given-names>L.-D.</given-names></name>
<name><surname>Faure</surname><given-names>S.</given-names></name>
<name><surname>McGonigal</surname><given-names>A.</given-names></name>
<name><surname>Horowitz</surname><given-names>T.</given-names></name>
<name><surname>Belquaid</surname><given-names>S.</given-names></name>
<name><surname>Bartolomei</surname><given-names>F.</given-names></name>
<name><surname>Guedj</surname><given-names>E.</given-names></name>
</person-group><article-title>Correlation between Fluorodeoxyglucose Positron Emission Tomography Brain Hypometabolism and Posttraumatic Stress Disorder Symptoms in Temporal Lobe Epilepsy</article-title><source>Epilepsia</source><year>2022</year><volume>63</volume><fpage>e74</fpage><lpage>e79</lpage><pub-id pub-id-type="doi">10.1111/epi.17300</pub-id><pub-id pub-id-type="pmid">35569022</pub-id>
</element-citation></ref><ref id="B36-pharmaceuticals-18-00271"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>M.</given-names></name>
<name><surname>Yu</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Hou</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Luo</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Ou</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Iron-Induced Neuronal Damage in a Rat Model of Post-Traumatic Stress Disorder</article-title><source>Neuroscience</source><year>2016</year><volume>330</volume><fpage>90</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.05.025</pub-id><pub-id pub-id-type="pmid">27208615</pub-id>
</element-citation></ref><ref id="B37-pharmaceuticals-18-00271"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Juh</surname><given-names>R.</given-names></name>
<name><surname>Pae</surname><given-names>C.-U.</given-names></name>
<name><surname>Kim</surname><given-names>T.-S.</given-names></name>
<name><surname>Lee</surname><given-names>C.-U.</given-names></name>
<name><surname>Choe</surname><given-names>B.</given-names></name>
<name><surname>Suh</surname><given-names>T.</given-names></name>
</person-group><article-title>Cerebral Glucose Metabolism in Corticobasal Degeneration Comparison with Progressive Supranuclear Palsy Using Statistical Mapping Analysis</article-title><source>Neurosci. Lett.</source><year>2005</year><volume>383</volume><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2005.03.057</pub-id><pub-id pub-id-type="pmid">15936506</pub-id>
</element-citation></ref><ref id="B38-pharmaceuticals-18-00271"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beliveau</surname><given-names>V.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>C.</given-names></name>
<name><surname>Steiger</surname><given-names>R.</given-names></name>
<name><surname>Gizewski</surname><given-names>E.R.</given-names></name>
<name><surname>Poewe</surname><given-names>W.</given-names></name>
<name><surname>Seppi</surname><given-names>K.</given-names></name>
<name><surname>Scherfler</surname><given-names>C.</given-names></name>
</person-group><article-title>Characterization and Diagnostic Potential of R2* in Early-Stage Progressive Supranuclear Palsy Variants</article-title><source>Park. Relat. Disord.</source><year>2022</year><volume>101</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2022.06.021</pub-id></element-citation></ref><ref id="B39-pharmaceuticals-18-00271"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dexter</surname><given-names>D.T.</given-names></name>
<name><surname>Jenner</surname><given-names>P.</given-names></name>
<name><surname>Schapira</surname><given-names>A.H.</given-names></name>
<name><surname>Marsden</surname><given-names>C.D.</given-names></name>
</person-group><article-title>Alterations in Levels of Iron, Ferritin, and Other Trace Metals in Neurodegenerative Diseases Affecting the Basal Ganglia. The Royal Kings and Queens Parkinson&#x02019;s Disease Research Group</article-title><source>Ann. Neurol.</source><year>1992</year><volume>32</volume><fpage>S94</fpage><lpage>S100</lpage><pub-id pub-id-type="doi">10.1002/ana.410320716</pub-id><pub-id pub-id-type="pmid">1510387</pub-id>
</element-citation></ref><ref id="B40-pharmaceuticals-18-00271"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pascoal-Faria</surname><given-names>P.</given-names></name>
<name><surname>Yalcin</surname><given-names>N.</given-names></name>
<name><surname>Fregni</surname><given-names>F.</given-names></name>
</person-group><article-title>Neural Markers of Neuropathic Pain Associated with Maladaptive Plasticity in Spinal Cord Injury</article-title><source>Pain. Pr.</source><year>2015</year><volume>15</volume><fpage>371</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1111/papr.12237</pub-id><pub-id pub-id-type="pmid">25169195</pub-id>
</element-citation></ref><ref id="B41-pharmaceuticals-18-00271"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoon</surname><given-names>E.J.</given-names></name>
<name><surname>Kim</surname><given-names>Y.K.</given-names></name>
<name><surname>Shin</surname><given-names>H.I.</given-names></name>
<name><surname>Lee</surname><given-names>Y.</given-names></name>
<name><surname>Kim</surname><given-names>S.E.</given-names></name>
</person-group><article-title>Cortical and White Matter Alterations in Patients with Neuropathic Pain after Spinal Cord Injury</article-title><source>Brain Res.</source><year>2013</year><volume>1540</volume><fpage>64</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2013.10.007</pub-id><pub-id pub-id-type="pmid">24125807</pub-id>
</element-citation></ref><ref id="B42-pharmaceuticals-18-00271"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meles</surname><given-names>S.K.</given-names></name>
<name><surname>Kok</surname><given-names>J.G.</given-names></name>
<name><surname>De Jong</surname><given-names>B.M.</given-names></name>
<name><surname>Renken</surname><given-names>R.J.</given-names></name>
<name><surname>de Vries</surname><given-names>J.J.</given-names></name>
<name><surname>Spikman</surname><given-names>J.M.</given-names></name>
<name><surname>Ziengs</surname><given-names>A.L.</given-names></name>
<name><surname>Willemsen</surname><given-names>A.T.M.</given-names></name>
<name><surname>van der Horn</surname><given-names>H.J.</given-names></name>
<name><surname>Leenders</surname><given-names>K.L.</given-names></name>
<etal/>
</person-group><article-title>The Cerebral Metabolic Topography of Spinocerebellar Ataxia Type 3</article-title><source>NeuroImage Clin.</source><year>2018</year><volume>19</volume><fpage>90</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.nicl.2018.03.038</pub-id><pub-id pub-id-type="pmid">30035006</pub-id>
</element-citation></ref><ref id="B43-pharmaceuticals-18-00271"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>F.</given-names></name>
<name><surname>Weihua</surname><given-names>L.</given-names></name>
<name><surname>Lirong</surname><given-names>O.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Xing</surname><given-names>W.</given-names></name>
</person-group><article-title>Quantitative Susceptibility Mapping in Spinocerebellar Ataxia Type 3/Machado&#x02013;Joseph Disease (SCA3/MJD)</article-title><source>Acta Radiol.</source><year>2020</year><volume>61</volume><fpage>520</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1177/0284185119868906</pub-id><pub-id pub-id-type="pmid">31450947</pub-id>
</element-citation></ref><ref id="B44-pharmaceuticals-18-00271"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koenig</surname><given-names>J.B.</given-names></name>
<name><surname>Dulla</surname><given-names>C.G.</given-names></name>
</person-group><article-title>Dysregulated Glucose Metabolism as a Therapeutic Target to Reduce Post-Traumatic Epilepsy</article-title><source>Front. Cell. Neurosci.</source><year>2018</year><volume>12</volume><elocation-id>350</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2018.00350</pub-id><pub-id pub-id-type="pmid">30459556</pub-id>
</element-citation></ref><ref id="B45-pharmaceuticals-18-00271"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peskind</surname><given-names>E.R.</given-names></name>
<name><surname>Petrie</surname><given-names>E.C.</given-names></name>
<name><surname>Cross</surname><given-names>D.J.</given-names></name>
<name><surname>Pagulayan</surname><given-names>K.</given-names></name>
<name><surname>McCraw</surname><given-names>K.</given-names></name>
<name><surname>Hoff</surname><given-names>D.</given-names></name>
<name><surname>Hart</surname><given-names>K.</given-names></name>
<name><surname>Yu</surname><given-names>C.-E.</given-names></name>
<name><surname>Raskind</surname><given-names>M.A.</given-names></name>
<name><surname>Cook</surname><given-names>D.G.</given-names></name>
<etal/>
</person-group><article-title>Cerebrocerebellar Hypometabolism Associated with Repetitive Blast Exposure Mild Traumatic Brain Injury in 12 Iraq War Veterans with Persistent Post-Concussive Symptoms</article-title><source>NeuroImage</source><year>2011</year><volume>54</volume><fpage>S76</fpage><lpage>S82</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.04.008</pub-id><pub-id pub-id-type="pmid">20385245</pub-id>
</element-citation></ref><ref id="B46-pharmaceuticals-18-00271"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Daglas</surname><given-names>M.</given-names></name>
<name><surname>Adlard</surname><given-names>P.A.</given-names></name>
</person-group><article-title>The Involvement of Iron in Traumatic Brain Injury and Neurodegenerative Disease</article-title><source>Front. Neurosci.</source><year>2018</year><volume>12</volume><elocation-id>981</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2018.00981</pub-id><pub-id pub-id-type="pmid">30618597</pub-id>
</element-citation></ref><ref id="B47-pharmaceuticals-18-00271"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moon</surname><given-names>Y.</given-names></name>
<name><surname>Han</surname><given-names>S.-H.</given-names></name>
<name><surname>Moon</surname><given-names>W.-J.</given-names></name>
</person-group><article-title>Patterns of Brain Iron Accumulation in Vascular Dementia and Alzheimer&#x02019;s Dementia Using Quantitative Susceptibility Mapping Imaging</article-title><source>J. Alzheimer&#x02019;s Dis.</source><year>2016</year><volume>51</volume><fpage>737</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.3233/JAD-151037</pub-id><pub-id pub-id-type="pmid">26890777</pub-id>
</element-citation></ref><ref id="B48-pharmaceuticals-18-00271"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Wei</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Liao</surname><given-names>J.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>C.</given-names></name>
<name><surname>Meng</surname><given-names>X.</given-names></name>
<name><surname>Xie</surname><given-names>D.</given-names></name>
<name><surname>Chao</surname><given-names>D.</given-names></name>
<name><surname>Fenoy</surname><given-names>A.J.</given-names></name>
<etal/>
</person-group><article-title>Low Cerebral Glucose Metabolism: A Potential Predictor for the Severity of Vascular Parkinsonism and Parkinson&#x02019;s Disease</article-title><source>Aging Dis.</source><year>2015</year><volume>6</volume><fpage>426</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.14336/AD.2015.0204</pub-id><pub-id pub-id-type="pmid">26618044</pub-id>
</element-citation></ref><ref id="B49-pharmaceuticals-18-00271"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Breijyeh</surname><given-names>Z.</given-names></name>
<name><surname>Karaman</surname><given-names>R.</given-names></name>
</person-group><article-title>Comprehensive Review on Alzheimer&#x02019;s Disease: Causes and Treatment</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>E5789</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25245789</pub-id></element-citation></ref><ref id="B50-pharmaceuticals-18-00271"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fawcett</surname><given-names>J.R.</given-names></name>
<name><surname>Bordayo</surname><given-names>E.Z.</given-names></name>
<name><surname>Jackson</surname><given-names>K.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Peterson</surname><given-names>J.</given-names></name>
<name><surname>Svitak</surname><given-names>A.</given-names></name>
<name><surname>Frey</surname><given-names>W.H.</given-names></name>
</person-group><article-title>Inactivation of the Human Brain Muscarinic Acetylcholine Receptor by Oxidative Damage Catalyzed by a Low Molecular Weight Endogenous Inhibitor from Alzheimer&#x02019;s Brain Is Prevented by Pyrophosphate Analogs, Bioflavonoids and Other Antioxidants</article-title><source>Brain Res.</source><year>2002</year><volume>950</volume><fpage>10</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(02)02981-5</pub-id><pub-id pub-id-type="pmid">12231224</pub-id>
</element-citation></ref><ref id="B51-pharmaceuticals-18-00271"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ding</surname><given-names>V.W.</given-names></name>
<name><surname>Chen</surname><given-names>R.H.</given-names></name>
<name><surname>McCormick</surname><given-names>F.</given-names></name>
</person-group><article-title>Differential Regulation of Glycogen Synthase Kinase 3beta by Insulin and Wnt Signaling</article-title><source>J. Biol. Chem.</source><year>2000</year><volume>275</volume><fpage>32475</fpage><lpage>32481</lpage><pub-id pub-id-type="doi">10.1074/jbc.M005342200</pub-id><pub-id pub-id-type="pmid">10913153</pub-id>
</element-citation></ref><ref id="B52-pharmaceuticals-18-00271"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moreno-Trevi&#x000f1;o</surname><given-names>M.G.</given-names></name>
<name><surname>Castillo-L&#x000f3;pez</surname><given-names>J.</given-names></name>
<name><surname>Meester</surname><given-names>I.</given-names></name>
</person-group><article-title>Moving Away from Amyloid Beta to Move on in Alzheimer Research</article-title><source>Front. Aging Neurosci.</source><year>2015</year><volume>7</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2015.00002</pub-id><pub-id pub-id-type="pmid">25657623</pub-id>
</element-citation></ref><ref id="B53-pharmaceuticals-18-00271"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Atamna</surname><given-names>H.</given-names></name>
<name><surname>Frey</surname><given-names>W.H.</given-names></name>
</person-group><article-title>A Role for Heme in Alzheimer&#x02019;s Disease: Heme Binds Amyloid Beta and Has Altered Metabolism</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>11153</fpage><lpage>11158</lpage><pub-id pub-id-type="doi">10.1073/pnas.0404349101</pub-id><pub-id pub-id-type="pmid">15263070</pub-id>
</element-citation></ref><ref id="B54-pharmaceuticals-18-00271"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Venters</surname><given-names>H.D.</given-names></name>
<name><surname>Bonilla</surname><given-names>L.E.</given-names></name>
<name><surname>Jensen</surname><given-names>T.</given-names></name>
<name><surname>Garner</surname><given-names>H.P.</given-names></name>
<name><surname>Bordayo</surname><given-names>E.Z.</given-names></name>
<name><surname>Najarian</surname><given-names>M.M.</given-names></name>
<name><surname>Ala</surname><given-names>T.A.</given-names></name>
<name><surname>Mason</surname><given-names>R.P.</given-names></name>
<name><surname>Frey</surname><given-names>W.H.</given-names></name>
</person-group><article-title>Heme from Alzheimer&#x02019;s Brain Inhibits Muscarinic Receptor Binding via Thiyl Radical Generation</article-title><source>Brain Res.</source><year>1997</year><volume>764</volume><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(97)00425-3</pub-id><pub-id pub-id-type="pmid">9295197</pub-id>
</element-citation></ref><ref id="B55-pharmaceuticals-18-00271"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Atamna</surname><given-names>H.</given-names></name>
<name><surname>Boyle</surname><given-names>K.</given-names></name>
</person-group><article-title>Amyloid-&#x003b2; Peptide Binds with Heme to Form a Peroxidase: Relationship to the Cytopathologies of Alzheimer&#x02019;s Disease</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>3381</fpage><lpage>3386</lpage><pub-id pub-id-type="doi">10.1073/pnas.0600134103</pub-id><pub-id pub-id-type="pmid">16492752</pub-id>
</element-citation></ref><ref id="B56-pharmaceuticals-18-00271"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>LeVine</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Exploring Potential Mechanisms Accounting for Iron Accumulation in the Central Nervous System of Patients with Alzheimer&#x02019;s Disease</article-title><source>Cells</source><year>2024</year><volume>13</volume><elocation-id>689</elocation-id><pub-id pub-id-type="doi">10.3390/cells13080689</pub-id><pub-id pub-id-type="pmid">38667304</pub-id>
</element-citation></ref><ref id="B57-pharmaceuticals-18-00271"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guzman-Martinez</surname><given-names>L.</given-names></name>
<name><surname>Maccioni</surname><given-names>R.B.</given-names></name>
<name><surname>Andrade</surname><given-names>V.</given-names></name>
<name><surname>Navarrete</surname><given-names>L.P.</given-names></name>
<name><surname>Pastor</surname><given-names>M.G.</given-names></name>
<name><surname>Ramos-Escobar</surname><given-names>N.</given-names></name>
</person-group><article-title>Neuroinflammation as a Common Feature of Neurodegenerative Disorders</article-title><source>Front. Pharmacol.</source><year>2019</year><volume>10</volume><elocation-id>1008</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2019.01008</pub-id><pub-id pub-id-type="pmid">31572186</pub-id>
</element-citation></ref><ref id="B58-pharmaceuticals-18-00271"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>Y.-W.</given-names></name>
<name><surname>Hung</surname><given-names>L.-C.</given-names></name>
<name><surname>Chen</surname><given-names>Y.-C.</given-names></name>
<name><surname>Wang</surname><given-names>W.-H.</given-names></name>
<name><surname>Lin</surname><given-names>C.-Y.</given-names></name>
<name><surname>Tzeng</surname><given-names>H.-H.</given-names></name>
<name><surname>Suen</surname><given-names>J.-L.</given-names></name>
<name><surname>Chen</surname><given-names>Y.-H.</given-names></name>
</person-group><article-title>Insulin Reduces Inflammation by Regulating the Activation of the NLRP3 Inflammasome</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>587229</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.587229</pub-id><pub-id pub-id-type="pmid">33679687</pub-id>
</element-citation></ref><ref id="B59-pharmaceuticals-18-00271"><label>59.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name><surname>Frey</surname><given-names>I.W.H.</given-names></name>
</person-group><article-title>Method for Administering Neurologic Agents to the Brain</article-title><source>U.S. Patent</source><patent>No. 5,624,898</patent><day>29 April 1997</day></element-citation></ref><ref id="B60-pharmaceuticals-18-00271"><label>60.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name><surname>Frey</surname><given-names>I.W.H.</given-names></name>
</person-group><article-title>Method for Administering Insulin to the Brain</article-title><source>U.S. Patent</source><patent>No. 6,313,093</patent><day>6 November 2001</day></element-citation></ref><ref id="B61-pharmaceuticals-18-00271"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reger</surname><given-names>M.A.</given-names></name>
<name><surname>Watson</surname><given-names>G.S.</given-names></name>
<name><surname>Frey</surname><given-names>W.H.</given-names></name>
<name><surname>Baker</surname><given-names>L.D.</given-names></name>
<name><surname>Cholerton</surname><given-names>B.</given-names></name>
<name><surname>Keeling</surname><given-names>M.L.</given-names></name>
<name><surname>Belongia</surname><given-names>D.A.</given-names></name>
<name><surname>Fishel</surname><given-names>M.A.</given-names></name>
<name><surname>Plymate</surname><given-names>S.R.</given-names></name>
<name><surname>Schellenberg</surname><given-names>G.D.</given-names></name>
<etal/>
</person-group><article-title>Effects of Intranasal Insulin on Cognition in Memory-Impaired Older Adults: Modulation by APOE Genotype</article-title><source>Neurobiol. Aging</source><year>2006</year><volume>27</volume><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2005.03.016</pub-id><pub-id pub-id-type="pmid">15964100</pub-id>
</element-citation></ref><ref id="B62-pharmaceuticals-18-00271"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reger</surname><given-names>M.A.</given-names></name>
<name><surname>Watson</surname><given-names>G.S.</given-names></name>
<name><surname>Green</surname><given-names>P.S.</given-names></name>
<name><surname>Wilkinson</surname><given-names>C.W.</given-names></name>
<name><surname>Baker</surname><given-names>L.D.</given-names></name>
<name><surname>Cholerton</surname><given-names>B.</given-names></name>
<name><surname>Fishel</surname><given-names>M.A.</given-names></name>
<name><surname>Plymate</surname><given-names>S.R.</given-names></name>
<name><surname>Breitner</surname><given-names>J.C.S.</given-names></name>
<name><surname>DeGroodt</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Intranasal Insulin Improves Cognition and Modulates Beta-Amyloid in Early AD</article-title><source>Neurology</source><year>2008</year><volume>70</volume><fpage>440</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000265401.62434.36</pub-id><pub-id pub-id-type="pmid">17942819</pub-id>
</element-citation></ref><ref id="B63-pharmaceuticals-18-00271"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Novak</surname><given-names>V.</given-names></name>
<name><surname>Mantzoros</surname><given-names>C.S.</given-names></name>
<name><surname>Novak</surname><given-names>P.</given-names></name>
<name><surname>McGlinchey</surname><given-names>R.</given-names></name>
<name><surname>Dai</surname><given-names>W.</given-names></name>
<name><surname>Lioutas</surname><given-names>V.</given-names></name>
<name><surname>Buss</surname><given-names>S.</given-names></name>
<name><surname>Fortier</surname><given-names>C.B.</given-names></name>
<name><surname>Khan</surname><given-names>F.</given-names></name>
<name><surname>Aponte Becerra</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>MemAID: Memory Advancement with Intranasal Insulin vs. Placebo in Type 2 Diabetes and Control Participants: A Randomized Clinical Trial</article-title><source>J. Neurol.</source><year>2022</year><volume>269</volume><fpage>4817</fpage><lpage>4835</lpage><pub-id pub-id-type="doi">10.1007/s00415-022-11119-6</pub-id><pub-id pub-id-type="pmid">35482079</pub-id>
</element-citation></ref><ref id="B64-pharmaceuticals-18-00271"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kellar</surname><given-names>D.</given-names></name>
<name><surname>Lockhart</surname><given-names>S.N.</given-names></name>
<name><surname>Aisen</surname><given-names>P.</given-names></name>
<name><surname>Raman</surname><given-names>R.</given-names></name>
<name><surname>Rissman</surname><given-names>R.A.</given-names></name>
<name><surname>Brewer</surname><given-names>J.</given-names></name>
<name><surname>Craft</surname><given-names>S.</given-names></name>
</person-group><article-title>Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer&#x02019;s Disease</article-title><source>J. Prev. Alzheimers Dis.</source><year>2021</year><volume>8</volume><fpage>240</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.14283/jpad.2021.14</pub-id><pub-id pub-id-type="pmid">34101779</pub-id>
</element-citation></ref><ref id="B65-pharmaceuticals-18-00271"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benedict</surname><given-names>C.</given-names></name>
<name><surname>Hallschmid</surname><given-names>M.</given-names></name>
<name><surname>Hatke</surname><given-names>A.</given-names></name>
<name><surname>Schultes</surname><given-names>B.</given-names></name>
<name><surname>Fehm</surname><given-names>H.L.</given-names></name>
<name><surname>Born</surname><given-names>J.</given-names></name>
<name><surname>Kern</surname><given-names>W.</given-names></name>
</person-group><article-title>Intranasal Insulin Improves Memory in Humans</article-title><source>Psychoneuroendocrinology</source><year>2004</year><volume>29</volume><fpage>1326</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2004.04.003</pub-id><pub-id pub-id-type="pmid">15288712</pub-id>
</element-citation></ref><ref id="B66-pharmaceuticals-18-00271"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmid</surname><given-names>V.</given-names></name>
<name><surname>Kullmann</surname><given-names>S.</given-names></name>
<name><surname>Gfr&#x000f6;rer</surname><given-names>W.</given-names></name>
<name><surname>Hund</surname><given-names>V.</given-names></name>
<name><surname>Hallschmid</surname><given-names>M.</given-names></name>
<name><surname>Lipp</surname><given-names>H.-P.</given-names></name>
<name><surname>H&#x000e4;ring</surname><given-names>H.-U.</given-names></name>
<name><surname>Preissl</surname><given-names>H.</given-names></name>
<name><surname>Fritsche</surname><given-names>A.</given-names></name>
<name><surname>Heni</surname><given-names>M.</given-names></name>
</person-group><article-title>Safety of Intranasal Human Insulin: A Review</article-title><source>Diabetes Obes. Metab.</source><year>2018</year><volume>20</volume><fpage>1563</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1111/dom.13279</pub-id><pub-id pub-id-type="pmid">29508509</pub-id>
</element-citation></ref><ref id="B67-pharmaceuticals-18-00271"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jauch-Chara</surname><given-names>K.</given-names></name>
<name><surname>Friedrich</surname><given-names>A.</given-names></name>
<name><surname>Rezmer</surname><given-names>M.</given-names></name>
<name><surname>Melchert</surname><given-names>U.H.</given-names></name>
<name><surname>Scholand-Engler</surname><given-names>H.G.</given-names></name>
<name><surname>Hallschmid</surname><given-names>M.</given-names></name>
<name><surname>Oltmanns</surname><given-names>K.M.</given-names></name>
</person-group><article-title>Intranasal Insulin Suppresses Food Intake via Enhancement of Brain Energy Levels in Humans</article-title><source>Diabetes</source><year>2012</year><volume>61</volume><fpage>2261</fpage><lpage>2268</lpage><pub-id pub-id-type="doi">10.2337/db12-0025</pub-id><pub-id pub-id-type="pmid">22586589</pub-id>
</element-citation></ref><ref id="B68-pharmaceuticals-18-00271"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kazkayasi</surname><given-names>I.</given-names></name>
<name><surname>Telli</surname><given-names>G.</given-names></name>
<name><surname>Nemutlu</surname><given-names>E.</given-names></name>
<name><surname>Uma</surname><given-names>S.</given-names></name>
</person-group><article-title>Intranasal Metformin Treatment Ameliorates Cognitive Functions via Insulin Signaling Pathway in ICV-STZ-Induced Mice Model of Alzheimer&#x02019;s Disease</article-title><source>Life Sci.</source><year>2022</year><volume>299</volume><fpage>120538</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2022.120538</pub-id><pub-id pub-id-type="pmid">35395244</pub-id>
</element-citation></ref><ref id="B69-pharmaceuticals-18-00271"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Novak</surname><given-names>P.</given-names></name>
<name><surname>Pimentel Maldonado</surname><given-names>D.A.</given-names></name>
<name><surname>Novak</surname><given-names>V.</given-names></name>
</person-group><article-title>Safety and Preliminary Efficacy of Intranasal Insulin for Cognitive Impairment in Parkinson Disease and Multiple System Atrophy: A Double-Blinded Placebo-Controlled Pilot Study</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0214364</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0214364</pub-id><pub-id pub-id-type="pmid">31022213</pub-id>
</element-citation></ref><ref id="B70-pharmaceuticals-18-00271"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iravanpour</surname><given-names>F.</given-names></name>
<name><surname>Dargahi</surname><given-names>L.</given-names></name>
<name><surname>Rezaei</surname><given-names>M.</given-names></name>
<name><surname>Haghani</surname><given-names>M.</given-names></name>
<name><surname>Heidari</surname><given-names>R.</given-names></name>
<name><surname>Valian</surname><given-names>N.</given-names></name>
<name><surname>Ahmadiani</surname><given-names>A.</given-names></name>
</person-group><article-title>Intranasal Insulin Improves Mitochondrial Function and Attenuates Motor Deficits in a Rat 6-OHDA Model of Parkinson&#x02019;s Disease</article-title><source>CNS Neurosci. Ther.</source><year>2021</year><volume>27</volume><fpage>308</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1111/cns.13609</pub-id><pub-id pub-id-type="pmid">33497031</pub-id>
</element-citation></ref><ref id="B71-pharmaceuticals-18-00271"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Born</surname><given-names>J.</given-names></name>
<name><surname>Lange</surname><given-names>T.</given-names></name>
<name><surname>Kern</surname><given-names>W.</given-names></name>
<name><surname>McGregor</surname><given-names>G.P.</given-names></name>
<name><surname>Bickel</surname><given-names>U.</given-names></name>
<name><surname>Fehm</surname><given-names>H.L.</given-names></name>
</person-group><article-title>Sniffing Neuropeptides: A Transnasal Approach to the Human Brain</article-title><source>Nat. Neurosci.</source><year>2002</year><volume>5</volume><fpage>514</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1038/nn0602-849</pub-id><pub-id pub-id-type="pmid">11992114</pub-id>
</element-citation></ref><ref id="B72-pharmaceuticals-18-00271"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bohringer</surname><given-names>A.</given-names></name>
<name><surname>Schwabe</surname><given-names>L.</given-names></name>
<name><surname>Richter</surname><given-names>S.</given-names></name>
<name><surname>Schachinger</surname><given-names>H.</given-names></name>
</person-group><article-title>Intranasal Insulin Attenuates the Hypothalamic&#x02013;Pituitary&#x02013;Adrenal Axis Response to Psychosocial Stress</article-title><source>Psychoneuroendocrinology</source><year>2008</year><volume>33</volume><fpage>1394</fpage><lpage>1400</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2008.08.002</pub-id><pub-id pub-id-type="pmid">18804330</pub-id>
</element-citation></ref><ref id="B73-pharmaceuticals-18-00271"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hanson</surname><given-names>L.R.</given-names></name>
<name><surname>Fine</surname><given-names>J.M.</given-names></name>
<name><surname>Renner</surname><given-names>D.B.</given-names></name>
<name><surname>Svitak</surname><given-names>A.L.</given-names></name>
<name><surname>Burns</surname><given-names>R.B.</given-names></name>
<name><surname>Nguyen</surname><given-names>T.M.</given-names></name>
<name><surname>Tuttle</surname><given-names>N.J.</given-names></name>
<name><surname>Marti</surname><given-names>D.L.</given-names></name>
<name><surname>Panter</surname><given-names>S.S.</given-names></name>
<name><surname>Frey</surname><given-names>W.H.</given-names></name>
</person-group><article-title>Intranasal Delivery of Deferoxamine Reduces Spatial Memory Loss in APP/PS1 Mice</article-title><source>Drug Deliv. Transl. Res.</source><year>2012</year><volume>2</volume><fpage>160</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1007/s13346-011-0050-2</pub-id><pub-id pub-id-type="pmid">25786865</pub-id>
</element-citation></ref><ref id="B74-pharmaceuticals-18-00271"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Zheng</surname><given-names>W.</given-names></name>
<name><surname>Shan</surname><given-names>Z.-Y.</given-names></name>
<name><surname>Teng</surname><given-names>W.-P.</given-names></name>
<name><surname>Wang</surname><given-names>Z.-Y.</given-names></name>
</person-group><article-title>Intranasal Deferoxamine Reverses Iron-Induced Memory Deficits and Inhibits Amyloidogenic APP Processing in a Transgenic Mouse Model of Alzheimer&#x02019;s Disease</article-title><source>Neurobiol. Aging</source><year>2013</year><volume>34</volume><fpage>562</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2012.05.009</pub-id><pub-id pub-id-type="pmid">22717236</pub-id>
</element-citation></ref><ref id="B75-pharmaceuticals-18-00271"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fine</surname><given-names>J.M.</given-names></name>
<name><surname>Baillargeon</surname><given-names>A.M.</given-names></name>
<name><surname>Renner</surname><given-names>D.B.</given-names></name>
<name><surname>Hoerster</surname><given-names>N.S.</given-names></name>
<name><surname>Tokarev</surname><given-names>J.</given-names></name>
<name><surname>Colton</surname><given-names>S.</given-names></name>
<name><surname>Pelleg</surname><given-names>A.</given-names></name>
<name><surname>Andrews</surname><given-names>A.</given-names></name>
<name><surname>Sparley</surname><given-names>K.A.</given-names></name>
<name><surname>Krogh</surname><given-names>K.M.</given-names></name>
<etal/>
</person-group><article-title>Intranasal Deferoxamine Improves Performance in Radial Arm Water Maze, Stabilizes HIF-1&#x003b1;, and Phosphorylates GSK3&#x003b2; in P301L Tau Transgenic Mice</article-title><source>Exp. Brain Res.</source><year>2012</year><volume>219</volume><fpage>381</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1007/s00221-012-3101-0</pub-id><pub-id pub-id-type="pmid">22547371</pub-id>
</element-citation></ref><ref id="B76-pharmaceuticals-18-00271"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fine</surname><given-names>J.M.</given-names></name>
<name><surname>Forsberg</surname><given-names>A.C.</given-names></name>
<name><surname>Stroebel</surname><given-names>B.M.</given-names></name>
<name><surname>Faltesek</surname><given-names>K.A.</given-names></name>
<name><surname>Verden</surname><given-names>D.R.</given-names></name>
<name><surname>Hamel</surname><given-names>K.A.</given-names></name>
<name><surname>Raney</surname><given-names>E.B.</given-names></name>
<name><surname>Crow</surname><given-names>J.M.</given-names></name>
<name><surname>Haase</surname><given-names>L.R.</given-names></name>
<name><surname>Knutzen</surname><given-names>K.E.</given-names></name>
<etal/>
</person-group><article-title>Intranasal Deferoxamine Affects Memory Loss, Oxidation, and the Insulin Pathway in the Streptozotocin Rat Model of Alzheimer&#x02019;s Disease</article-title><source>J. Neurol. Sci.</source><year>2017</year><volume>380</volume><fpage>164</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2017.07.028</pub-id><pub-id pub-id-type="pmid">28870559</pub-id>
</element-citation></ref><ref id="B77-pharmaceuticals-18-00271"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fine</surname><given-names>J.M.</given-names></name>
<name><surname>Kosyakovsky</surname><given-names>J.</given-names></name>
<name><surname>Baillargeon</surname><given-names>A.M.</given-names></name>
<name><surname>Tokarev</surname><given-names>J.V.</given-names></name>
<name><surname>Cooner</surname><given-names>J.M.</given-names></name>
<name><surname>Svitak</surname><given-names>A.L.</given-names></name>
<name><surname>Faltesek</surname><given-names>K.A.</given-names></name>
<name><surname>Frey</surname><given-names>W.H.</given-names></name>
<name><surname>Hanson</surname><given-names>L.R.</given-names></name>
</person-group><article-title>Intranasal Deferoxamine Can Improve Memory in Healthy C57 Mice, Suggesting a Partially Non-Disease-Specific Pathway of Functional Neurologic Improvement</article-title><source>Brain Behav.</source><year>2020</year><volume>10</volume><fpage>e01536</fpage><pub-id pub-id-type="doi">10.1002/brb3.1536</pub-id><pub-id pub-id-type="pmid">31960628</pub-id>
</element-citation></ref><ref id="B78-pharmaceuticals-18-00271"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crapper McLachlan</surname><given-names>D.R.</given-names></name>
<name><surname>Dalton</surname><given-names>A.J.</given-names></name>
<name><surname>Kruck</surname><given-names>T.P.</given-names></name>
<name><surname>Bell</surname><given-names>M.Y.</given-names></name>
<name><surname>Smith</surname><given-names>W.L.</given-names></name>
<name><surname>Kalow</surname><given-names>W.</given-names></name>
<name><surname>Andrews</surname><given-names>D.F.</given-names></name>
</person-group><article-title>Intramuscular Desferrioxamine in Patients with Alzheimer&#x02019;s Disease</article-title><source>Lancet</source><year>1991</year><volume>337</volume><fpage>1304</fpage><lpage>1308</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(91)92978-B</pub-id><pub-id pub-id-type="pmid">1674295</pub-id>
</element-citation></ref><ref id="B79-pharmaceuticals-18-00271"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gordon</surname><given-names>G.S.</given-names></name>
<name><surname>Ambruso</surname><given-names>D.R.</given-names></name>
<name><surname>Robinson</surname><given-names>W.A.</given-names></name>
<name><surname>Githens</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Intranasal Administration of Deferoxamine to Iron Overloaded Patients</article-title><source>Am. J. Med. Sci.</source><year>1989</year><volume>297</volume><fpage>280</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1097/00000441-198905000-00002</pub-id><pub-id pub-id-type="pmid">2640419</pub-id>
</element-citation></ref><ref id="B80-pharmaceuticals-18-00271"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Craft</surname><given-names>S.</given-names></name>
<name><surname>Baker</surname><given-names>L.D.</given-names></name>
<name><surname>Montine</surname><given-names>T.J.</given-names></name>
<name><surname>Minoshima</surname><given-names>S.</given-names></name>
<name><surname>Watson</surname><given-names>G.S.</given-names></name>
<name><surname>Claxton</surname><given-names>A.</given-names></name>
<name><surname>Arbuckle</surname><given-names>M.</given-names></name>
<name><surname>Callaghan</surname><given-names>M.</given-names></name>
<name><surname>Tsai</surname><given-names>E.</given-names></name>
<name><surname>Plymate</surname><given-names>S.R.</given-names></name>
<etal/>
</person-group><article-title>Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment</article-title><source>Arch. Neurol.</source><year>2012</year><volume>69</volume><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2011.233</pub-id><pub-id pub-id-type="pmid">21911655</pub-id>
</element-citation></ref><ref id="B81-pharmaceuticals-18-00271"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peng</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Fan</surname><given-names>Y.</given-names></name>
<name><surname>Tang</surname><given-names>F.</given-names></name>
<name><surname>Hou</surname><given-names>C.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Jiang</surname><given-names>G.</given-names></name>
</person-group><article-title>Low-Dose Intranasal Insulin Improves Cognitive Function and Suppresses the Development of Epilepsy</article-title><source>Brain Res.</source><year>2020</year><volume>1726</volume><fpage>146474</fpage><pub-id pub-id-type="doi">10.1016/j.brainres.2019.146474</pub-id><pub-id pub-id-type="pmid">31557476</pub-id>
</element-citation></ref><ref id="B82-pharmaceuticals-18-00271"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lioutas</surname><given-names>V.-A.</given-names></name>
<name><surname>Novak</surname><given-names>V.</given-names></name>
</person-group><article-title>Intranasal Insulin Neuroprotection in Ischemic Stroke</article-title><source>Neural Regen. Res.</source><year>2016</year><volume>11</volume><fpage>400</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.179040</pub-id><pub-id pub-id-type="pmid">27127468</pub-id>
</element-citation></ref><ref id="B83-pharmaceuticals-18-00271"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hanson</surname><given-names>L.R.</given-names></name>
<name><surname>Roeytenberg</surname><given-names>A.</given-names></name>
<name><surname>Martinez</surname><given-names>P.M.</given-names></name>
<name><surname>Coppes</surname><given-names>V.G.</given-names></name>
<name><surname>Sweet</surname><given-names>D.C.</given-names></name>
<name><surname>Rao</surname><given-names>R.J.</given-names></name>
<name><surname>Marti</surname><given-names>D.L.</given-names></name>
<name><surname>Hoekman</surname><given-names>J.D.</given-names></name>
<name><surname>Matthews</surname><given-names>R.B.</given-names></name>
<name><surname>Frey</surname><given-names>W.H.</given-names></name>
<etal/>
</person-group><article-title>Intranasal Deferoxamine Provides Increased Brain Exposure and Significant Protection in Rat Ischemic Stroke</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2009</year><volume>330</volume><fpage>679</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1124/jpet.108.149807</pub-id><pub-id pub-id-type="pmid">19509317</pub-id>
</element-citation></ref><ref id="B84-pharmaceuticals-18-00271"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fine</surname><given-names>J.M.</given-names></name>
<name><surname>Forsberg</surname><given-names>A.C.</given-names></name>
<name><surname>Renner</surname><given-names>D.B.</given-names></name>
<name><surname>Faltesek</surname><given-names>K.A.</given-names></name>
<name><surname>Mohan</surname><given-names>K.G.</given-names></name>
<name><surname>Wong</surname><given-names>J.C.</given-names></name>
<name><surname>Arneson</surname><given-names>L.C.</given-names></name>
<name><surname>Crow</surname><given-names>J.M.</given-names></name>
<name><surname>Frey</surname><given-names>W.H.</given-names></name>
<name><surname>Hanson</surname><given-names>L.R.</given-names></name>
</person-group><article-title>Intranasally-Administered Deferoxamine Mitigates Toxicity of 6-OHDA in a Rat Model of Parkinson&#x02019;s Disease</article-title><source>Brain Res.</source><year>2014</year><volume>1574</volume><fpage>96</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2014.05.048</pub-id><pub-id pub-id-type="pmid">24928620</pub-id>
</element-citation></ref><ref id="B85-pharmaceuticals-18-00271"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frey</surname><given-names>W.H.</given-names></name>
</person-group><article-title>Intranasal Insulin to Treat and Protect against Posttraumatic Stress Disorder</article-title><source>J. Nerv. Ment. Dis.</source><year>2013</year><volume>201</volume><fpage>638</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1097/NMD.0b013e318298302e</pub-id><pub-id pub-id-type="pmid">23817163</pub-id>
</element-citation></ref><ref id="B86-pharmaceuticals-18-00271"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shaughness</surname><given-names>M.</given-names></name>
<name><surname>Acs</surname><given-names>D.</given-names></name>
<name><surname>Brabazon</surname><given-names>F.</given-names></name>
<name><surname>Hockenbury</surname><given-names>N.</given-names></name>
<name><surname>Byrnes</surname><given-names>K.R.</given-names></name>
</person-group><article-title>Role of Insulin in Neurotrauma and Neurodegeneration: A Review</article-title><source>Front. Neurosci.</source><year>2020</year><volume>14</volume><elocation-id>547175</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2020.547175</pub-id><pub-id pub-id-type="pmid">33100956</pub-id>
</element-citation></ref><ref id="B87-pharmaceuticals-18-00271"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jaiswal</surname><given-names>S.</given-names></name>
<name><surname>Collier</surname><given-names>S.</given-names></name>
<name><surname>Acs</surname><given-names>D.</given-names></name>
<name><surname>Byrnes</surname><given-names>K.</given-names></name>
</person-group><article-title>Intranasal Insulin Reduces Glucose Uptake Chronically after Rodent Spinal Cord Injury: Role of Diminished Inflammation</article-title><source>J. Nucl. Med.</source><year>2022</year><volume>63</volume><fpage>2955</fpage></element-citation></ref><ref id="B88-pharmaceuticals-18-00271"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yao</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Hao</surname><given-names>J.</given-names></name>
<name><surname>Duan</surname><given-names>H.-Q.</given-names></name>
<name><surname>Zhao</surname><given-names>C.-X.</given-names></name>
<name><surname>Sun</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Fan</surname><given-names>B.-Y.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>W.-X.</given-names></name>
<etal/>
</person-group><article-title>Deferoxamine Promotes Recovery of Traumatic Spinal Cord Injury by Inhibiting Ferroptosis</article-title><source>Neural Regen. Res.</source><year>2019</year><volume>14</volume><fpage>532</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.245480</pub-id><pub-id pub-id-type="pmid">30539824</pub-id>
</element-citation></ref><ref id="B89-pharmaceuticals-18-00271"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brabazon</surname><given-names>F.</given-names></name>
<name><surname>Wilson</surname><given-names>C.M.</given-names></name>
<name><surname>Jaiswal</surname><given-names>S.</given-names></name>
<name><surname>Reed</surname><given-names>J.</given-names></name>
<name><surname>Frey</surname><given-names>W.H.</given-names></name>
<name><surname>Byrnes</surname><given-names>K.R.</given-names></name>
</person-group><article-title>Intranasal Insulin Treatment of an Experimental Model of Moderate Traumatic Brain Injury</article-title><source>J. Cereb. Blood Flow. Metab.</source><year>2017</year><volume>37</volume><fpage>3203</fpage><lpage>3218</lpage><pub-id pub-id-type="doi">10.1177/0271678X16685106</pub-id><pub-id pub-id-type="pmid">28058996</pub-id>
</element-citation></ref><ref id="B90-pharmaceuticals-18-00271"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Gong</surname><given-names>X.</given-names></name>
<name><surname>Xiang</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Xiang</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
</person-group><article-title>Integrated Transcriptome and Metabolome Analysis to Investigate the Mechanism of Intranasal Insulin Treatment in a Rat Model of Vascular Dementia</article-title><source>Front. Pharmacol.</source><year>2023</year><volume>14</volume><elocation-id>1182803</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2023.1182803</pub-id><pub-id pub-id-type="pmid">37256231</pub-id>
</element-citation></ref><ref id="B91-pharmaceuticals-18-00271"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bou Khalil</surname><given-names>R.</given-names></name>
<name><surname>Khoury</surname><given-names>E.</given-names></name>
<name><surname>Koussa</surname><given-names>S.</given-names></name>
</person-group><article-title>Linking Multiple Pathogenic Pathways in Alzheimer&#x02019;s Disease</article-title><source>World J. Psychiatry</source><year>2016</year><volume>6</volume><fpage>208</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.5498/wjp.v6.i2.208</pub-id><pub-id pub-id-type="pmid">27354962</pub-id>
</element-citation></ref><ref id="B92-pharmaceuticals-18-00271"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ardanaz</surname><given-names>C.G.</given-names></name>
<name><surname>Ram&#x000ed;rez</surname><given-names>M.J.</given-names></name>
<name><surname>Solas</surname><given-names>M.</given-names></name>
</person-group><article-title>Brain Metabolic Alterations in Alzheimer&#x02019;s Disease</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>3785</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23073785</pub-id><pub-id pub-id-type="pmid">35409145</pub-id>
</element-citation></ref><ref id="B93-pharmaceuticals-18-00271"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koenig</surname><given-names>A.M.</given-names></name>
<name><surname>Mechanic-Hamilton</surname><given-names>D.</given-names></name>
<name><surname>Xie</surname><given-names>S.X.</given-names></name>
<name><surname>Combs</surname><given-names>M.F.</given-names></name>
<name><surname>Cappola</surname><given-names>A.R.</given-names></name>
<name><surname>Xie</surname><given-names>L.</given-names></name>
<name><surname>Detre</surname><given-names>J.A.</given-names></name>
<name><surname>Wolk</surname><given-names>D.A.</given-names></name>
<name><surname>Arnold</surname><given-names>S.E.</given-names></name>
</person-group><article-title>Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-Controlled Crossover Study</article-title><source>Alzheimer Dis. Assoc. Disord.</source><year>2017</year><volume>31</volume><fpage>107</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1097/WAD.0000000000000202</pub-id><pub-id pub-id-type="pmid">28538088</pub-id>
</element-citation></ref><ref id="B94-pharmaceuticals-18-00271"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burns</surname><given-names>D.K.</given-names></name>
<name><surname>Alexander</surname><given-names>R.C.</given-names></name>
<name><surname>Welsh-Bohmer</surname><given-names>K.A.</given-names></name>
<name><surname>Culp</surname><given-names>M.</given-names></name>
<name><surname>Chiang</surname><given-names>C.</given-names></name>
<name><surname>O&#x02019;Neil</surname><given-names>J.</given-names></name>
<name><surname>Evans</surname><given-names>R.M.</given-names></name>
<name><surname>Harrigan</surname><given-names>P.</given-names></name>
<name><surname>Plassman</surname><given-names>B.L.</given-names></name>
<name><surname>Burke</surname><given-names>J.R.</given-names></name>
<etal/>
</person-group><article-title>Safety and Efficacy of Pioglitazone for the Delay of Cognitive Impairment in People at Risk of Alzheimer&#x02019;s Disease (TOMMORROW): A Prognostic Biomarker Study and a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial</article-title><source>Lancet Neurol.</source><year>2021</year><volume>20</volume><fpage>537</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(21)00043-0</pub-id><pub-id pub-id-type="pmid">34146512</pub-id>
</element-citation></ref><ref id="B95-pharmaceuticals-18-00271"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Esterline</surname><given-names>R.</given-names></name>
<name><surname>Oscarsson</surname><given-names>J.</given-names></name>
<name><surname>Burns</surname><given-names>J.</given-names></name>
</person-group><article-title>A Role for Sodium Glucose Cotransporter 2 Inhibitors (SGLT2is) in the Treatment of Alzheimer&#x02019;s Disease?</article-title><source>Int. Rev. Neurobiol.</source><year>2020</year><volume>155</volume><fpage>113</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/bs.irn.2020.03.018</pub-id><pub-id pub-id-type="pmid">32854852</pub-id>
</element-citation></ref><ref id="B96-pharmaceuticals-18-00271"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reich</surname><given-names>N.</given-names></name>
<name><surname>H&#x000f6;lscher</surname><given-names>C.</given-names></name>
</person-group><article-title>The Neuroprotective Effects of Glucagon-like Peptide 1 in Alzheimer&#x02019;s and Parkinson&#x02019;s Disease: An in-Depth Review</article-title><source>Front. Neurosci.</source><year>2022</year><volume>16</volume><elocation-id>970925</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2022.970925</pub-id><pub-id pub-id-type="pmid">36117625</pub-id>
</element-citation></ref><ref id="B97-pharmaceuticals-18-00271"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Yue</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Zhou</surname><given-names>F.</given-names></name>
</person-group><article-title>Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson&#x02019;s Disease Mice</article-title><source>Int. J. Nanomed.</source><year>2024</year><volume>19</volume><fpage>10401</fpage><lpage>10414</lpage><pub-id pub-id-type="doi">10.2147/IJN.S479670</pub-id><pub-id pub-id-type="pmid">39430307</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-18-00271-f001"><label>Figure 1</label><caption><p>The relationship between brain glucose hypometabolism (BGHM), brain iron accumulation (BIA), and many other mechanisms involved in Alzheimer&#x02019;s disease pathology as well as other neurological disorders, is outlined. Drugs targeting BGHM and BIA, such as intranasally administered insulin and deferoxamine, respectively, are promising therapies for Alzheimer&#x02019;s disease and other neurological disorders as shown. (This schematic drawing was created using art elements from Servier Medical Art Commons Attribution 3.0 Unported License. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License).</p></caption><graphic xlink:href="pharmaceuticals-18-00271-g001" position="float"/></fig></floats-group></article>